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The skeleton is an exquisitely sensitive and archetypal T3-target tissue that demonstrates the critical role for
thyroid hormones during development, linear growth, and adult bone turnover and maintenance. Thyrotox-
icosis is an established cause of secondary osteoporosis, and abnormal thyroid hormone signaling has recently
been identified as a novel risk factor for osteoarthritis. Skeletal phenotypes in genetically modified mice have
faithfully reproduced genetic disorders in humans, revealing the complex physiological relationship between
centrally regulated thyroid status and the peripheral actions of thyroid hormones. Studies in mutant mice also
established the paradigm that T3 exerts anabolic actions during growth and catabolic effects on adult bone.
Thus, the skeleton represents an ideal physiological system inwhich to characterize thyroid hormone transport,
metabolism, and action during development, adulthood and in response to injury. Future analysis of T3 action
in individual skeletal cell lineages will provide new insights into cell-specific molecular mechanisms and may
ultimately identify novel therapeutic targets for chronic degenerative diseases such as osteoporosis and osteo-
arthritis. This review provides a comprehensive analysis of the current state-of-the-art.
I. Introduction
THE ESSENTIAL REQUIREMENT for thyroid hor-mones during linear growth and skeletal maturation
is well established and has been recognized for 125 years.
Indeed, the association between goiter, cretinism, devel-
opmental retardation and short stature had been known
for centuries, and the therapeutic use of burnt sponge and
seaweed in the treatment of goiter dates back to 1600 BC
in China. Paracelcus provided the first clinical description
of endemic goiter and congenital idiocy in 1603. Between
1811–1813 Bernard Courtois discovered iodine, Joseph
Gay-Lussac identified it as an element and Humphrey
Davy recognized it as a halogen (1). However Jean-Fran-
cois Coindet, in 1820, was the first to use iodine as a
treatment for goiter and Gaspard Chatin, in the 1850’s,
was the first to show that iodine in plants prevented cre-
tinism and goiter in endemic regions. Thomas Curling, in
1850, described cretinism in association with athyreosis,
while William Gull provided the causal link between lack
of a thyroid gland and cretinism in 1873. William Ord
extendedGull’s observations and chaired the first detailed
report on hypothyroidism by the Clinical Society of Lon-
don in 1878 linking cretinism, myxedema and cachexia
strumipriva (decay due to lack of goiter) as a single entity.
Indeed, in a lecture to the German Society of Surgery in
1883, the Swiss Nobel Laureate Theodor Kocher de-
scribed cachexia strumipriva as a specific disease that in-
cluded“decreased growth inheight” following removal of
the thyroid gland. Ultimately, these events led to the first
organotherapy for hypothyroidism by George Murray in
1891, although the ancient Chinese had used animal thy-
roid tissue as a treatment for goiter as early as 643 AD
(1–3).
Alongside the emergence of hypothyroidism as a rec-
ognizeddisease,Charles de Saint-Yves,AntonioTesta and
Guiseppe Flajani reported the first cases of goiter, palpi-
tations and exophthalmos between 1722–1802, although
these featureswerenot linkedat that time.CalebParryhad
recognized in 1825, while Robert Graves independently
recognized and also published in 1835, the link between
hypertrophic goiter and exophthalmos (1, 3). Carl Adolf
von Basedow extended Graves’ description in 1840 by
adding palpitations, weight loss, diarrhea, tremor, rest-
lessness, perspiration, amenorrhea, myxedema of the
lower leg and orbital tissue hypertrophy to describe the
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syndrome more completely. In 1886, Paul Möbius pro-
posed the cause of these symptoms was increased thyroid
function and Murray supported this view in 1891 at the
time of his organotherapy for hypothyroidism (1, 3). Co-
incidentally, in the same year of 1891, Friedrich Von
Recklinghausen reported a patient with thyrotoxicosis
and multiple fractures and was the first to identify the
relationship between the thyroid and the adult skeleton (4,
5). Since then a role for thyroid hormones in bone and
mineral metabolism has become well established.
During the last 25 years the role of thyroid hormones in
bone and cartilage biology has attracted considerable and
growing attention, leading to important advances in un-
derstanding the consequences of thyroid disease on the
developing and adult skeleton.Major progress in defining
the mechanisms of thyroid hormone action in bone has
followed and led to new insights into thyroid-related skel-
etal disorders. As a result, the role of the hypothalamic-
pituitary-thyroid (HPT) axis in skeletal pathophysiology
has become a high profile subject. It is only now that ex-
perimental tools are becoming available to allow deter-
minationof theprecise cellular andmolecularmechanisms
that underlie thyroid hormone actions in the skeleton.
This reviewwill discuss our current understandingby con-
sidering the published literature up to December 31st
2015.
II. Thyroid hormone physiology
A. Hypothalamic-pituitary-thyroid axis
Synthesis and release of the prohormone 3,5,3,5-L-
tetraiodothyronine (thyroxine, T4) and the active thyroid
hormone 3,5,3-L-triiodothyronine (T3) are controlled by
anegative feedback loopmediatedby theHPTaxis (Figure
1) (6). Thyrotropin releasing hormone (TRH) is secreted
by the hypothalamic paraventricular nucleus and acts on
pituitary thyrotrophs to stimulate release of thyrotropin
(thyroid-stimulating hormone, TSH). TSH subsequently
acts via the TSH receptor (TSHR) on thyroid follicular
cells to stimulate cell proliferation and the synthesis and
secretion of T4 and T3 (7). T3, derived predominantly
from local metabolism of T4, acts via thyroid hormone
receptors  and  (TR, TR) in the hypothalamus and
pituitary to inhibit synthesis and secretion of TRH and
TSH (8–11). Normal euthyroid status is maintained by a
negative feedback loop that establishes a physiological in-
verse relationship between TSH and circulating T3 and
T4, thus defining theHPT axis set point (12, 13). Systemic
thyroid hormone and TSH concentrations vary signifi-
cantly among individuals, indicating each person has a
unique set point (12). Twin studies indicate the set point
is genetically determined with heritability for free T3
(fT3), free T4 (fT4) and TSH of 65% (14), and candidate
Figure 1.
Hypothalamic-pituitary-thyroid axis
The thyroid gland secretes the prohormone T4 and the active hormone
T3 and circulating concentrations are regulated by a classical endocrine
negative feedback loop that maintains an inverse physiological
relationship between TSH, and T4 and T3.
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gene and genome wide association studies (GWAS) have
identified quantitative trait loci (15–17).
B. TSH action
The glycoprotein hormone TSH is composed of com-
mon - and unique -subunits. The TSHR is a G-protein
coupled receptor consisting of ligand binding, ecto- and
transmembrane domains (Figure 2) (18). Although cAMP
is the major second messenger following activation of the
TSHR in thyroid follicular cells, alternative downstream
signaling pathways have been implicated in both thyroid
and extrathyroidal tissues (19–22). In the thyroid the
TSHR associates with various G proteins (23), and Gs
and Gq are thought to compete for
activation by the TSHR (20, 24).
C. Extrathyroidal actions of TSH
The TSHR has been proposed to
have diverse functions in extrathy-
roidal tissues, although their physi-
ological importance has not been es-
tablished. Thus, TSHR expression
has been reported in anterior pitu-
itary, brain, pars tuberalis, bone, or-
bital preadipocytes and fibroblasts,
kidney, ovary and testis, skin and
hair follicles, heart, adipose tissue, as
well as hematopoietic and immune
cells (19, 25–28). These data suggest
direct actions of TSH, for example,
in the regulation of seasonal repro-
duction (29–31), bone turnover
(32), pathogenesis of Graves’ or-
bitopathy (33–35), and immuno-
modulatory responses in the bone
marrow (36–43), gut (42, 43) and
skeleton (38).
D. Thyroid hormone transport
Uptake of thyroid hormones into
peripheral tissues and entry into tar-
get cells ismediated by specificmem-
brane transporter proteins (Figure 3)
(44), including monocarboxylate
transporters MCT8 and MCT10,
the organic anion transporter pro-
tein-1C1 (OATP1C1), and the non-
specific L-type amino acid transport-
ers 1 and 2 (LAT1, LAT2) (45). The
best-characterized specific trans-
porter MCT8 is expressed widely
and its physiological importance has
been demonstrated by inactivating
mutations of MCT8 that cause the
Allan–Herndon–Dudley X-linked
psychomotor retardation syndrome
(OMIM #300523) (46, 47).
Figure 2.
TSH action
Binding of TSH to the TSHR results in activation of G protein coupled downstream signaling
including the (i) adenylyl cyclase (AC), cAMP, protein kinase A (PKA) and the cAMP response
element binding (CREB) protein or (ii) phospholipase C (PLC), inositol triphosphate (IP3) and
intracellular calcium pathway or the (iii) PLC, diacylglycerol (DAG), protein kinase C (PKC), and
signal transducer and activator of transcription 3 (STAT3) pathway.
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E. Thyroid hormone metabolism
T4 is derived from thyroid gland secretion, while most
circulating T3 is generated by deiodination of T4 in pe-
ripheral tissues. Although the circulating fT4 concentra-
tion is fourfold greater than fT3, the TR-binding affinity
for T3 is 15-fold higher than its affinity for T4 (48). Thus,
T4 must be converted to T3 for mediation of genomic
thyroid hormone action (Figure 3) (49). Three iodothy-
ronine deiodinasesmetabolize thyroid hormones to active
or inactive products (6, 50, 51). The type 1 deiodinase
(DIO1) is inefficient with an apparent Michaelis constant
(Km) of 10-6-10-7 M, and catalyzes removal of inner or
outer ring iodine atoms in equimolar proportions to gen-
erate T3, reverse T3 (rT3), or 3,3-diiodothyronine (T2)
depending on the substrate. Most of the circulating T3 is
derived from conversion of T4 to T3 by DIO1, which is
expressed mainly in the thyroid gland, liver and kidney.
Nevertheless, its physiological role remains uncertain be-
cause serum T3 concentrations are normal in Dio1-/-
knockout mice (52). Activity of DIO2 in skeletal muscle
may also contribute to circulating T3, although this role
probably differs between species (6, 49, 53–55). DIO2
(Km 10-9 M) is more efficient than DIO1 and catalyzes
outer ring deiodination to generate T3 fromT4. The phys-
iological role of DIO2 is thus to control the intracellular
T3 concentration and saturation of the nuclear TR in tar-
Figure 3.
Thyroid hormone action in bone cells
(A) In hypothyroidism, despite maximum DIO2 (D2) and minimum DIO3 (D3) activities, TR1 remains unliganded and bound to corepressor thus
inhibiting T3 target gene transcription.
(B) In the euthyroid state D2 and D3 activities are regulated to optimize ideal intracellular T3 availability resulting in displacement of corepressor
and physiological transcriptional activity of TR1.
(C) In thyrotoxicosis, despite maximum D3 and minimum D2 activities, supra-physiological intracellular T3 concentrations result in increased TR1
activation and enhanced T3 target gene responses.
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get tissues (56–58). Importantly, DIO2 protects tissues
from the detrimental effects of hypothyroidismbecause its
low Km permits efficient local conversion of T4 to T3. T4
treatment of cells in which MCT8 and DIO2 are coex-
pressed results in increasedT3 target gene expression (59),
indicating thyroid hormone uptake and metabolism co-
ordinately regulate T3 responsiveness. By contrast, DIO3
(Km 10-9 M) irreversibly inactivates T3 or prevents T4
being activated by inner ring deiodination to generate T2
or rT3, respectively.Thephysiological role ofDIO3 is thus
to prevent or limit access of thyroid hormones to specific
tissues at critical times during development and in tissue
repair (6, 49, 51).
Consistent with this, DIO2 and DIO3 are expressed in
T3-target cells, including the central nervous system
(CNS), cochlea, retina, heart and skeleton (49, 60–65),
and expression of both enzymes is regulated in a temporo-
spatial and tissue-specific manner (51, 66, 67). Acting to-
gether, DIO2 and DIO3 thus control cellular T3 avail-
ability (49). For example, during fetal growth, high levels
of DIO3 in placenta, uterus and fetal tissues protect de-
veloping organs from exposure to inappropriate levels of
T3 and facilitate cell proliferation (68). At birth, DIO3
declines rapidly while expression of DIO2 increases to
trigger cell differentiation and tissue maturation during
postnatal development (49–51). The temporo-spatial and
tissue-specific regulated expression of both DIO2 and
DIO3 (66) and the TR and TR nuclear receptors (69)
combine to provide a complex and co-ordinated system
for fine control of T3 availability and action in individual
cell types.
F. Nuclear actions of thyroid hormones
TR and TR are members of the nuclear receptor
superfamily (70, 71), acting as ligand-inducible transcrip-
tion factors that regulate expression of T3-target genes
(Figure 3). In mammals, THRA encodes three C-terminal
variants of TR. TR1 is a functional receptor that binds
both DNA and T3, whereas TR2 and TR3 fail to bind
T3 and act as antagonists in vitro (72). A promoter within
intron 7 of mouse Thra gives rise to two truncated vari-
ants, TR1 and TR2, which are potent dominant-
negative antagonists in vitro, although their physiological
role is unclear (73).Two truncatedTR1proteinsp28and
p43 arise from alternate start codon usage and are pro-
posed to mediate T3 actions in mitochondria or non-
genomic responses (74, 75). THRB encodes twoN-termi-
nal TR variants, TR1 and TR2, both of which act as
functional receptors. Two further transcripts, TR3 and
TR3, have been described but their physiological role is
uncertain (76, 77). TR1 and TR1 are expressedwidely,
but their relative concentrations differ during develop-
ment and in adulthooddue to tissue-specific and temporo-
spatial regulation (69), so that most T3-target tissues are
either predominantly TR1 or TR1 responsive or lack
isoform specificity. Expression of TR2, however, is
markedly restricted. In the hypothalamus and pituitary, it
mediates inhibitory actions of thyroid hormones on TRH
andTSH expression to control theHPT axis (8, 78), while
in cochlea and retina TR2 is an important regulator of
sensory development (79, 80).
In the nucleus, TRs form heterodimers with retinoid X
receptors (RXR) and bindT3 response elements (TREs) in
target gene promoters to regulate transcription. Unligan-
ded TRs compete with T3-bound TRs for DNA response
elements. They are potent transcriptional repressors and
have critical roles during development (81–84). Unligan-
ded TRs interact with corepressor proteins, including nu-
clear receptor corepressor (NCoR) and the silencing me-
diator for retinoid and TR (SMRT), which recruit histone
deacetylases and inhibit gene transcription (85, 86). Li-
gand-bound TRs interact with steroid receptor coactiva-
tor 1 (SRC1) and other related coactivators in a hormone-
dependent fashion leading to target gene activation. The
opposing chromatin-modifying effects of unliganded and
liganded TRs greatly enhance the magnitude of the tran-
scriptional response to T3 (87–89). In addition to positive
stimulatory effects, T3 also mediates transcriptional re-
pression to inhibit expression of key target genes, includ-
ing TSH. Although negative regulatory effects are physi-
ologically critical, underlyingmolecularmechanisms have
not been fully characterized (88).
G. Nongenomic actions of thyroid hormones
Nongenomic effects of thyroid hormones include ac-
tions that do not directly influence nuclear gene expres-
sion.Nongenomic actions frequently have a short latency,
are not affected by inhibitors of transcription and trans-
lation, and have agonist and antagonist affinity and ki-
netics divergent from classical nuclear hormone actions
(90). These rapid responses are associated with second
messenger pathways including (i) the phospholipase C
(PLC), inositol triphosphate (IP3), diacyl glycerol (DAG),
protein kinase C (PKC) and intracellular Ca2 signaling
pathway; (ii) the adenylyl cyclase, protein kinase A (PKA)
and the cyclic AMP-response element binding protein
(CREB) pathway; and (iii) the Ras, Raf1 serine/threonine
kinase, mitogen activated protein kinase pathway.
Nongenomic actions of thyroid hormones have been
described at the plasma membrane, in the cytoplasm and
mitochondria (74, 88). The V3 integrin has been re-
ported to mediate cell surface responses to T4 acting, for
example, via the MAPK pathway to stimulate cell prolif-
eration and angiogenesis (91, 92). TR also mediates
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rapid responses to T3, acting via the
PI3K/AKT/mTOR/p70S6K and PI3K
pathways (93–99), whereas palmi-
tolyated TR activates the nitric ox-
ide/protein kinase G2/Src pathway
to stimulate MAPK and PI3K/AKT
downstream signaling responses
that mediate rapid T3 actions in os-
teoblastic cells (75).
III. Skeletal physiology
Bones of the skull vault form di-
rectly from mesenchyme via in-
tramembranous ossification
whereas longbones developona car-
tilage scaffold by endochondral os-
sification (Figure 4). Four key cell
types are involved in these develop-
mental programs, and they are essen-
tial for linear growth in the postnatal
period and maintenance of the skel-
eton in later life.
A. Bone and cartilage cell lineages
Chondrocytes
Chondrocytes are the first skeletal
cell type to arise during development
(100). In early embryogenesis mes-
enchyme precursors condense and
define a template for the future skel-
eton. These cells differentiate into
chondrocytes that proliferate and se-
crete a matrix containing aggrecan,
elastin and type II collagen to form a
cartilage anlage ormodel of the skel-
etal element.Cells at the center of the
anlage stop proliferating and differ-
entiate into prehypertrophic and
then hypertrophic chondrocytes
(101). Hypertrophic chondrocytes
increase rapidly in size, synthesize a
matrix rich in type X collagen and
induce formation of calcified carti-
lage before finally undergoing apo-
ptosis (102). Initiation of chondro-
genesis requires bone morphogenic
protein (BMP) signaling and the
transcription factor SOX9 acting in
association with SOX5 and SOX6.
Indian hedgehog (IHH) stimulates
chondrocyte proliferation directly
Figure 4.
Intramembranous and endochondral ossification
(A) Postnatal day 1 skull vault stained with alizarin red (bone) and alcian blue (cartilage) showing
sutures and fontanelles.
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but also ensures that sufficient chondrocyte proliferation
occursby increasingparathyroidhormone-relatedpeptide
(PTHrP) signaling, which inhibits chondrocyte hypertro-
phic differentiation. Canonical Wnt signaling promotes
hypertrophic differentiation via inhibition of SOX9
whereas fibroblast growth factor (FGF) 18 inhibits both
proliferation and differentiation of chondrocytes (102,
103).
Osteoblasts
Bone-forming osteoblasts comprise 5% of bone cells
and derive from multipotent mesenchymal stem cells that
can differentiate into chondrocytes, osteoblasts or adi-
pocytes. Osteoblast maturation comprises precursor cell
commitment, cell proliferation, type I collagen deposition
andmatrixmineralization. Following bone formation, os-
teoblasts may differentiate into bone lining cells or osteo-
cytes, or undergo apoptosis (104, 105). In SOX9-express-
ingmesenchymal progenitors, osteoblastogenesis requires
induction of two critical transcription factors RUNX2
and Osterix (105, 106). Subsequent differentiation is reg-
ulated by the IHH, PTH, Notch, canonical Wnt, BMP,
insulin-like growth factor-1 (IGF-1) and FGF signaling
pathways (105, 107, 108).
Osteocytes
Osteocytes comprise 90%–95% of bone cells and de-
rive from osteoblasts that have become embedded in bone
matrix. Osteocyte dendritic processes ramify though net-
works of canaliculi and sense fluid shear stresses, com-
municating via gap junctions (109, 110). Mechanical
stresses and localized microdamage stimulate osteocytes
to release cytokines and chemotactic signals, or induce
apoptosis. In general, increased mechanical stress stimu-
lates local osteoblastic bone formation, whereas reduced
loading or microdamage results in osteoclastic bone re-
sorption (111, 112).Osteocytes are thusmechano-sensors
that control bone modeling and remodeling through their
regulation of osteoclasts via the RANKL/RANK pathway
and osteoblasts via modulation of Wnt signaling
(113–115).
Osteoclasts
Osteoclasts comprise 1%–2% of bone cells. They are
polarized multinucleated cells derived from fusion of
mononuclear–myeloidprecursors that resorbbonematrix
and mineral. Attachment to bone is mediated by V3
integrin that interacts with bone matrix proteins. These
interactions lead to formation of an actin ring and sealing
zonewithpolarizationof theosteoclast into ruffledborder
and basolateral membrane regions (116). Carbonic anhy-
drase II generates protons and bicarbonate within the os-
teoclast cytoplasm (117) and the HCO3
- is exchanged for
extracellular chloride at the basolateral membrane by a
specific Cl-/HCO3
- channel. An osteoclast-specific pump
(H-ATPase) transports protons across the ruffled bor-
der, while the CLCN7 channel transports chloride simul-
taneously. Within resorption lacuna, the acidic environ-
ment dissolves hydroxyapatite to release Ca2 and
HPO4
2-, while a secreted cysteine protease, cathepsin K,
digestsorganicbonematrix.Thedegradationproducts are
endocytosed at the ruffled border, transported across the
cytoplasm in tartrate-resistant acid phosphatase-rich ves-
icles and released at the basolateral membrane by exocy-
tosis (117). Commitment of hematopoietic stem cells to
the myeloid lineage is regulated by the PU.1 and micro-
ophthalmia-associated (MITF) transcription factors,
which induce colony stimulating factor receptor (CSF-1R)
expression. Macrophage colony stimulating factor/
CSF-1R signaling stimulates expression of receptor acti-
vator of nuclear factor B (RANK), leading to osteoclast
precursor commitment. RANK ligand/RANK signaling
induces the key transcription factors, nuclear factor B
(NFB) and nuclear factor of activatedT cells cytoplasmic
1 (NFATc1), leading to osteoclast differentiation and fu-
sion (108, 118).
B. Intramembranous ossification
The flat bones of the face and skull form by intramem-
branous ossification, which occurs in the absence of a car-
tilage scaffold (Figure 4A-B). Mesenchyme progenitors,
located within vascularized connective tissue membranes,
condense into nodules and differentiate to bone-forming
osteoblasts. The osteoblasts secrete an osteoid matrix of
type I collagen and chondroitin sulfate which mineralizes
to form an ossification center. The surrounding mesen-
chyme forms the periosteum and cells at the inner surface
differentiate into lining osteoblasts. Progressive bone for-
mation results in extension of bony spicules and fusion of
adjacent ossification centers (119).
C. Endochondral ossification
Endochondral ossification is the
process bywhich long bones formon
a cartilage scaffold (Figure 4C-D)
(101). Mesenchyme precursors con-
dense and differentiate into chon-
drocytes, which proliferate and se-
(B) Schematic representation of intramembranous bone formation at a skull suture.
(C) Proximal tibial section at postnatal day 21 growth plate stained with alcian blue (cartilage)
and van Gieson (bone matrix, red).
(D) Schematic representation of the growth plate.
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crete a matrix containing type II collagen and
proteoglycans that forms a cartilage template. At the pri-
mary ossification center a coordinated program of chon-
drocyte proliferation, hypertrophic differentiation and
apoptosis leads to mineralization of cartilage. Subse-
quently, vascular invasion and migration of osteoblasts
enables replacement of mineralized cartilage with trabec-
ular bone. Concurrently, peripheral mesenchyme precur-
sors in the perichondrium differentiate into osteoblasts
and form a collar of cortical bone. Secondary ossification
centers form at the ends of long bones and remain sepa-
rated from the primary ossification center by the epiphy-
seal growth plates where endochondral ossification
continues.
D. Linear growth and bone maturation
Epiphyseal growth plates at both ends of developing
bones comprise the reserve, proliferative, prehypertrophic
and hypertrophic zones, together with primary and sec-
ondary spongiosa (Figure 4C-D) (101). The reserve zone
contains uniform chondrocytes with a low proliferation
index. Cells progress to the proliferative zone, become
flattened, increase type II collagen synthesis and form lon-
gitudinal columns. As chondrocytes mature they express
alkaline phosphatase, undergo terminal hypertrophic dif-
ferentiation, secrete type X collagen and increase in vol-
ume by 10-fold (120, 121). Finally, apoptosis of hyper-
trophic chondrocytes results in release of angiogenic
factors that stimulate vascular invasion and migration of
osteoblasts and osteoclasts, leading to remodeling of cal-
cified cartilage and formation of trabecular bone. This
ordered process mediates linear growth until adulthood
(101). Synchronously, the diameter of the long bone di-
aphysis increases by osteoblastic deposition of cortical
bone beneath the periosteum, and the marrow cavity ex-
pands as a consequence of osteoclastic bone resorption at
the endosteal surface.
Progression of endochondral os-
sification and linear growth is tightly
regulated by a local feedback loop
involving IHH and PTHrP (101,
122), and other factors including
systemic hormones (thyroid hor-
mones, growth hormone (GH),
IGF-1, glucocorticoids, sex ste-
roids), various cytokines and growth
factors (BMPs, FGFs, vascular endo-
thelial growth factors) that act in a
paracrine and autocrine manner
(101). Linear growth continues until
fusion of the growth plates during
puberty, but bone mineralization
and consolidation of bonemass con-
tinues until peak bone mass is
achieved during the third to fourth
decade (101, 123, 124).
E. The bone remodeling cycle
Functional integrity and strength
of the adult skeleton ismaintained in
a continuous process of repair by the
‘bone remodeling cycle’ (125) (Fig-
ure 5). The basic multicellular unit
(BMU) of bone remodeling com-
prises osteoclasts and osteoblasts
whose activities are orchestrated by
osteocytes (113, 126, 127). Over
95% of the surface of the adult skel-
eton is normally quiescent because
osteocytes exert resting inhibition of
Figure 5.
Bone remodeling compartment and “Basic Multicellular Unit” of the bone remodeling cycle.
The bone remodeling cycle is initiated and orchestrated by osteocytes. Bone remodeling results
from changes in mechanical load, structural microdamage or exposure to systemic or paracrine
factors. Monocyte/macrophage precursors differentiate to mature osteoclasts and resorb bone.
Differentiation is induced by macrophage colony-stimulating factor (CSF) (M-CSF) and receptor
activator of NFkB ligand (RANKL) and inhibited by osteoprotegerin (OPG). During reversal,
osteoblastic progenitors are recruited to the site of resorption, synthesize osteoid, and mineralize
new bone to repair the defect.
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both osteoclastic bone resorption and osteoblastic bone
formation (117).
Under basal conditions, osteocytes secrete transform-
ing growth factor- (TGF) and sclerostin, which inhibit
osteoclastogenesis and Wnt-activated osteoblastic bone
formation, respectively. Increased load or local mi-
crodamage results in a fall in local TGF levels (128) and
activation of bone lining cells leads to recruitment of os-
teoclast progenitors. Osteocytes and bone lining cells ex-
pressM-CSF and RANKL, the two cytokines required for
osteoclastogenesis (114, 125). RANKL acts via several
downstream signaling molecules, including c-fos, NF-kB,
NFATc1, MAPK and TNF receptor-associated factor-6
(129–131). RANKL also induces expression of V3 in-
tegrin in osteoclast precursors, which signals via c-src to
induce activation of small GTPases that are critical for
formation of the actin ring sealing zone and osteoclast
migration and survival. In addition to RANKL, osteo-
blasts and bone marrow stromal cells express osteopro-
tegerin (OPG). OPG is a secreted decoy receptor for
RANKL and functions as the physiological inhibitor of
RANK–RANKL signaling (117, 132). Thus, the RANKL:
OPG ratio determines osteoclast differentiation and ac-
tivity. This ratio is regulated by systemic hormones and
local cytokines that control bone remodeling and include
estrogen, PTH, glucocorticoids, TNF-, IL-1 and prosta-
glandin E2 (133).
Following this 30–40 day resorption phase, reversal
cells remove undigested matrix fragments from the bone
surface, and local paracrine signals released from de-
graded matrix recruit osteoblasts that initiate bone for-
mation. Over the next 150 days, osteoblasts secrete and
mineralize new bonematrix (osteoid) to fill the resorption
cavity. Although commitment of mesenchyme precursors
to the osteoblast lineage requires both Wnt and BMP sig-
naling, the canonical Wnt pathway subsequently acts as
the master regulator of osteogenesis (134–136). Physio-
logical negative regulation of canonical Wnt signaling is
mediated by the osteocyte, which secretes soluble factors
(sclerostin, Dickkopf1-related protein 1 (DKK1) and se-
creted frizzled related protein 1 (SFRP1)) that interfere
with the interaction betweenWnt ligands and their recep-
tor and coreceptor (113, 126). During the process of bone
formation, some osteoblasts become embedded within
newly formed bone and undergo terminal differentiation
to osteocytes. Secretion of sclerostin and other Wnt in-
hibitors by these osteocytes leads to cessation of bone for-
mation and a return to the quiescent state in which osteo-
blasts become bone-lining cells (113, 126).
This cycle of targeted bone modeling and remodeling
enables the adult skeleton to repair old or damaged bone,
react to changes in mechanical stress and respond rapidly
to the demands of mineral homeostasis.
IV. Skeletal target cells and downstream signaling
pathways
A. TSH actions in chondrocytes, osteoblasts and
osteoclasts
Expression of TSHR and its ligands in skeletal cells
TSHR is expressed predominantly in thyroid follicular
cells, but expression in chondrocytes, osteoblasts and os-
teoclasts suggests TSH exerts direct actions in cartilage
and bone (32, 137). Although pituitary TSH functions as
a systemic hormone, local expression of TSHR ligands in
bonehas alsobeen investigated.TSHandTSH subunits
are not expressed in primary human or mouse osteoblasts
or osteoclasts (138, 139). Nevertheless, an alternative
splice variant of Tshb (Tshb-sv) has been identified in
mousebonemarrow (140, 141). Expressionof this variant
in bone marrow-derived macrophages activated cAMP in
cocultured, stably transfected TSHR-overexpressing
CHO cells (142). mRNA encoding the isoform was also
identified at low levels in primary mouse osteoblasts but
not osteoclasts (139). The alternative TSHR ligand, thy-
rostimulin, is also expressed inosteoblasts andosteoclasts,
and studies of Gpb5-/- mice lacking thyrostimulin indi-
cated thyrostimulin regulates osteoblastic bone formation
during early skeletal development. However, the under-
lying mechanisms remain unknown, as thyrostimulin
failed to influence osteoblast proliferation or differentia-
tion, or activate cAMP, ERK, P38 MAPK or AKT signal-
ing pathways in primary osteoblasts or bonemarrow stro-
mal cells in vitro (139).
Chondrocytes
Only limited information has been published regarding
the TSHR in cartilage. In mesenchymal stem cells, TSH
stimulated self-renewal and expression of chondrogenic
marker genes suggesting TSH may increase chondrocyte
differentiation (143). Growth plate cartilage and cultured
chondrocytes express TSHR, and treatment with TSH in-
creased cAMP activity and decreased expression of SOX9
and type IIa collagen expression in primary chondrocytes
(137).
Initial studies, therefore, suggest TSHR signalingmight
inhibit chondrocyte differentiation (Figure 6).
Osteoblasts
Expression of TSHR in UMR106 rat osteosarcoma
cells was reported in 1998 (144) and, subsequently, ex-
pression of TSHR mRNA and protein was identified in
osteoblasts and osteoclasts (32, 38, 138, 139, 145). The
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lack of TSH and  expression in osteoblasts and oste-
oclasts (138, 139), indicates TSH does not have local au-
tocrine effects in these cells. Nevertheless, treatment of
osteoblastswith TSH in vitro inhibited osteoblastogenesis
and reduced expression of type I collagen, bone sialopro-
tein and osteocalcin (32). Inhibition of low-density lipo-
protein (LDL) receptor-relatedprotein5 (LRP5)mRNAin
these studies suggested the effects of TSH on osteoblasto-
genesis and function might be mediated viaWnt signaling
(32).
By contrast, Sampath et al and Baliram et al showed
that TSH stimulates osteoblast differentiation and func-
tion (142, 145). Furthermore, in ES cell cultures, TSH
stimulated osteoblastic differentiation via protein kinase
C and the noncanonical Wnt pathway components Friz-
zled and Wnt5a (146). In human SaOS2 osteosarcoma
cells, TSH also stimulated proliferation and differentia-
tion as measured by alkaline phosphatase, and increased
IGF-1 and IGF-II mRNA expression together with com-
plex regulatory effects on IGFBPs and their proteases
(147). Finally, TSH stimulated -arrestin 1 leading to ac-
tivation of ERK, P38MAPKandAKT signaling pathways
and osteoblast differentiation in stably transfected human
osteoblasticU2OS-TSHRcells that overexpress theTSHR
(148).
Despite these contrasting findings, Tsai et al had pre-
viously shown only low levels of TSHR expression, TSH
binding and cAMP activation in human osteoblasts and
concluded TSH was unlikely to have a physiological role
(149). Further studies alsodemonstratedonly low levels of
TSHRprotein in calvarial osteoblasts, and in these studies
treatment with TSH and TSHR-stimulating antibodies
failed to induce cAMP and TSH did not affect osteoblast
differentiation or function (38, 138).
Figure 6.
Actions of T3 and TSH in skeletal cell
(A) T3 and TSH actions in osteocytes have not been investigated and it is unknown whether osteocytes express thyroid hormone transporters,
deiodinases, TRs or the TSHR.
(B) Chondrocytes express MCT8, MCT10 and LAT1 transporters, DIO3 (D3), TRs (predominantly TR), and TSHR. T3 inhibits proliferation and
stimulates prehypertrophic and hypertrophic chondrocyte differentiation, while TSH might inhibit proliferation and matrix synthesis.
(C) Osteoblasts express MCT8 and LAT1/2 transporters, the DIO2 (D2) and D3, TRs (predominantly TR), and TSHR. Most studies indicate T3
stimulates osteoblast differentiation and bone formation. Contradictory data suggest TSH may stimulate, inhibit or have no effect on osteoblast
differentiation and function.
(D) Osteoclasts express MCT8, D3, TRs and the TSHR. Currently it is unclear if T3 acts directly in osteoclasts or whether indirect effects in the
osteoblast lineage mediate its actions. Most studies indicate TSH inhibits osteoclast differentiation and function.
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Overall, findings have been interpreted to suggest that
changes in TNF, RANKL, OPG and interleukin 1 sig-
naling in response to TSH might be mediated via an al-
ternative G-protein and not by cAMP (32, 38, 150). Thus,
although the TSHR is expressed in osteoblasts, in vitro
data are contradictory suggesting TSH may inhibit, en-
hance or have no effect on osteoblast differentiation and
function (Figure 6). Furthermore, the physiological sec-
ondmessenger pathway that lies downstream of activated
TSHR in osteoblasts has not yet been defined.
Osteoclasts
Bassett et al showedmouse osteoclasts express low lev-
els of TSHR protein, but treatment with TSH and TSHR-
stimulating antibodies did not affect osteoclast differen-
tiation and function or elicit a cAMP response (138).
Nevertheless, most studies have shown TSH inhibits os-
teoclast formation and function. Thus, treatment of
monocyte precursors with TSH inhibited osteoclastogen-
esis and dentine resorption (32, 38, 145), while TSH and
TSHR-stimulating antibodies also inhibited osteoclasto-
genesis in mouse embryonic stem cell (ESC) cultures
treated with M-CSF, RANKL, vitamin D and dexameth-
asone (150). Zhang et al also showed TSH inhibits tar-
trate-resistant acid phosphatase (TRAP), MMP-9 and ca-
thepsin K expression and osteoclastogenesis in
RAW264.7 cells (151).
In vitro studies usingbonemarrowcultures fromTshr-/-
mice revealed that inhibitory effects of TSH on osteoclas-
togenesis weremediated by TNF acting via disruption of
activator protein 1 (AP-1) and NF-B signaling (32, 38,
152), and the pathogenesis of bone loss inTshr-/-micewas
proposed to bemediated by elevated levels ofTNF (153).
Nevertheless, the mechanisms of bone loss in Tshr-/-mice
appear complex and the underlying signaling pathways
remain incompletely defined. Thus, TSH inhibited oste-
oclastogenesis in WT mice and TNF stimulated oste-
oclastogenesis in WT and Tshr-/-mice. Accordingly, TSH
inhibited TNF via AP-1 and RANKL-NFB signaling
pathways in osteoclasts in vitro (153), although in previ-
ous studies TSH had been shown to stimulate TNF in
ES-cell derived osteoblasts (146). Together, these findings
were proposed as a counter-regulatory mechanism of
TNF inhibition and stimulation in osteoclasts and os-
teoblasts, respectively (153).
Overall, most studies indicate that TSHR signaling in-
hibits osteoclastogenesis and function by complex mech-
anisms primarily involving TNF (Figure 6).
B. T3 actions in chondrocytes, osteoblasts and
osteoclasts
Expression of thyroid hormone transporters
The thyroid hormone transporter MCT8 is expressed
and regulated by thyroid status in growth plate chondro-
cytes, osteoblasts andosteoclasts (61, 154).Recent studies
indicate OATP1c1 is not expressed in the skeleton (154).
MCT10 appears to be the major transporter expressed in
the growthplate (155),while expressionof the less specific
LAT1 and LAT2 transporters has also been detected in
bone (61, 154, 155). Nevertheless, the physiological im-
portance and possible redundancy of thyroid hormone
transporters in the skeleton has yet to be determined (Fig-
ure 6).
Expression of deiodinases
Thyroid hormone metabolism occurs in skeletal cells
(156).AlthoughDIO1 isnot expressed in cartilageorbone
(61, 156), the activating enzyme DIO2 is expressed in os-
teoblasts (60, 61).Dio2mRNA has also been detected in
the embryonic mouse skeleton as early as embryonic day
E14.5 and increases until E18.5 (157, 158). In the devel-
oping chick growth plate, DIO2 activity is restricted to the
perichondrium (159), indicating the enzyme has a role in
local regulation of thyroid hormone signaling during fetal
bone development. DIO2 is also expressed in primary
mesenchymal stem cells, in which expression is strongly
induced following treatment with BMP-7 (160). The in-
activating DIO3 enzyme is present in all skeletal cell lin-
eages particularly during development, with the highest
levels of activity in growth plate chondrocytes prior to
weaning (61, 157). Together, these data suggest that con-
trol of tissue T3 availability byDIO2 andDIO3 is likely to
be important for skeletal development, linear growth and
osteoblast function (Figure 6).
Expression of thyroid hormone receptors
TRs are expressed at sites of intramembranous and en-
dochondral bone formation. The localization of TR pro-
teins to reserve and proliferative zone growth plate chon-
drocytes, but not hypertrophic cells (161, 162), suggests
that progenitor cells and proliferating chondrocytes are
primary T3-target cells but differentiated chondrocytes
lose the ability to respond toT3. BothTR1 andTR1 are
expressed in bone and quantitativeRT-PCR studies reveal
that levels of TR1 are at least 10-fold greater than TR1
(163, 164), suggesting TR1 is the predominantmediator
of T3 action in bone. Nevertheless, other studies also in-
dicate TR may play a role (165–167).
TR1, TR2, and TR1 are expressed in reserve and
proliferative zone epiphyseal growth plate chondrocytes
(161, 162, 168–173) and in immortalized osteoblastic
cells from several species (170, 174–181), as well as in
primary osteoblasts and osteoblastic bone marrow stro-
mal cells (175, 182, 183). However, it is unknown
whether TRs are expressed in osteocytes (184, 185). Thy-
roid hormones stimulate osteoclastic bone resorption
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(186, 187), but this effectmay be indirect andmediated by
T3-responsive osteoblasts (188, 189). Although immuno-
localization of TR proteins and detection of TR mRNAs
by in situ hybridization in osteoclasts from pathological
human osteophytes and osteoclastoma tissue were re-
ported in early studies (168, 174, 190), TRantibodies lack
sufficient sensitivity to detect expression of endogenous
protein and it remains uncertain whether osteoclasts ex-
press functional TRs or respond directly to T3.
Overall, current studies indicate that reserve zone and
proliferating chondrocytes, osteoblastic bone marrow
stromal cells and osteoblasts are major T3-target cells in
bone and predominantly express TR (Figure 6).
Chondrocytes
Hypertrophic chondrocyte differentiation andvascular
invasion of cartilage are sensitive to thyroid status (191);
findings that support early studies (192–194) and rein-
force the critical importance of T3 for endochondral os-
sification and linear growth. Nevertheless, studies of T3
action in chondrocytes cultured in monolayers are con-
flicting due to the species, source of chondrocytes, and
culture conditions studied (171, 195–199).Consequently,
several three-dimensional culture systems have been de-
vised to investigate the T3-regulated differentiation po-
tential of chondrocytes in vitro (196, 200–202). T3 treat-
ment of chondrogenic ATDC5 cells, mesenchymal stem
cells, primary growth plate chondrocytes and long bone
organ cultures inhibits cell proliferation and concomi-
tantly stimulates hypertrophic chondrocyte differentia-
tion and cellular apoptosis (161, 197, 203–209). T3 pro-
motes hypertrophic differentiation by induction of cyclin-
dependent kinase inhibitors to regulate the G1-S cell cycle
checkpoint (200). Subsequently, T3 stimulates BMP4 sig-
naling, synthesis of a collagenXmatrix, and expression of
alkaline phosphatase and MMP13 to facilitate progres-
sion of hypertrophic differentiation and cartilage miner-
alization (120, 161, 197, 203–206). In addition, T3 reg-
ulation of growth plate chondrocyte proliferation and
differentiation in vitro involves activation of IGF-1 and
Wnt signaling (210–212).
The regulatory effects of T3 on endochondral ossifica-
tion and linear growth in vivo involve interactions with
key pathways that regulate growth plate maturation in-
cluding IHH, PTHrP, IGF1, Wnt, BMPs, FGFs and leptin
(213–215). IHH, PTHrP and BMP receptor-1A partici-
pate in a negative feedback loop that promotes growth
plate chondrocyte proliferation and inhibits differentia-
tion thereby controlling the rate of linear growth. The
set-point of this feedback loop is sensitive to thyroid status
(162, 216) and regulated by local thyroid hormone me-
tabolism andT3 availability (159). Furthermore, T3 stim-
ulates expressionof genes involved in cartilagematrix syn-
thesis, mineralization and degradation; including matrix
proteoglycans (203, 204, 217–221) and collagen degrad-
ing enzymes such as aggrecanase-2 (a disintegrin andmet-
alloproteinase with thrombospondin motifs1, AD-
AMTS5) and MMP13 (205, 222, 223), as well as BMP4,
Wnt4 and FGFR3 (120, 210, 224–226).
In summary, thyroid hormone is essential for coordi-
nated progression of endochondral ossification, acting to
stimulate genes that control chondrocyte maturation and
cartilage matrix synthesis, mineralization and
degradation.
Osteoblasts
Althoughprimaryosteoblasts (170, 172, 227–233) and
several osteoblastic cell lines (176, 178–181, 223, 234–
245) respond to T3 in vitro, the consequences of T3 stim-
ulation vary considerably and depend on species, the an-
atomical origin of osteoblasts (183, 246–248), cell type,
passage number, cell confluence, stage of differentiation,
and the dose and duration of T3 treatment. Thus, T3 has
been shown to stimulate, inhibit, or have no effect on
osteoblastic cell proliferation. A general consensus, how-
ever, indicates that T3 stimulates osteoblast proliferation
and differentiation and bone matrix synthesis, modifica-
tion andmineralization. T3 increases expression of osteo-
calcin, osteopontin, type I collagen, alkaline phosphatase,
IGF-I and its regulatory binding proteins (IGF1BP-2 and
–4), interleukin-6 and –8, MMP9, MMP13, tissue inhib-
itor of metalloproteinase- 1 (TIMP-1), FGFR1 leading to
activation ofMAPK-signaling, and also regulates theWnt
pathway (165, 179, 180, 223, 227, 229, 232, 235–237,
243–245, 249–259). Furthermore, IGFBP-6 interacts di-
rectly with TR1 to inhibit T3-stimulated increases in al-
kaline phosphatase activity and osteocalcin mRNA in os-
teoblastic cells (260). Thus, T3 stimulates osteoblast
activity both directly and indirectly via complex pathways
involvingmanygrowth factors andcytokines.T3mayalso
potentiate osteoblast responses to PTH (233) by modu-
lating expression of PTH/PTHrP receptor (176).
Despite themanypotentialT3-target genes identified in
osteoblasts, little information is available regardingmech-
anisms by which their expression is modulated, and T3
regulation may involve other signaling pathways. For ex-
ample, T3 regulates osteoblastic cell morphology, cyto-
skeleton, and cell-cell contacts in vitro (234, 239, 240). In
addition, T3 stimulates osteocalcin via nongenomic ac-
tions mediated by suppression of Src (261). T3 also phos-
phorylates and activates p38 MAPK and stimulates os-
teocalcin expression in MC3T3 cells (250, 262), a
pathway that is enhanced by AMPK activation (263) but
inhibited by cAMP (264) and Rho-kinase (265). A recent
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study further demonstrated that nongenomic signaling in
osteoblasts and osteosarcoma cells is mediated by a
plasma membrane bound N-terminal truncated isoform
of TR1 that is palmitoylated and interacts with caveolin-
containing membrane domains. Acting via this isoform,
T3 stimulated osteoblast proliferation and survival via in-
creased intracellular Ca2, NO and cGMP leading to ac-
tivation of protein kinase GII, Src and ERK (75).
Overall, many studies in primary cultured and immor-
talized osteoblastic cells demonstrate the complexities of
T3 action in bone and emphasize the importance of the
cellular system under study. Many of these T3 actions
involve interactions with bone matrix and local paracrine
and autocrine factors via mechanisms that have yet to be
determined.
Osteoclasts
Thyroid hormone excess results in increased osteoclast
numbers and activity in vivo leading to bone loss. Oste-
oclasts express TR1 andTR1mRNAs but it is not clear
whether functional receptors are expressed because TR
antibodies lack sufficient sensitivity to detect endogenous
proteins. Studies of mixed cultures containing osteoclast
lineage cells and bone marrow stromal cells have been
contradictory and it is not clear whether stimulation of
osteoclastic bone resorption results fromdirectT3-actions
in osteoclasts or indirect effects mediated by primary ac-
tions in cells of the osteoblast lineage (186–188, 254,
266). Studies of fetal long bone and calvarial cultures
(173, 267, 268) implicated various cytokines and growth
factors including IGF-1 (269, 270), prostaglandins (186),
interleukins (271), TGF (238, 272), and interferon-
(186) as mediators of secondary responses in osteoclasts.
Similarly, treatment of immortalized osteoblasts or pri-
mary bone marrow stromal cells resulted in increased
RANKL, interleukin 6 (IL-6), IL-8 and prostaglandin E2
expression, and inhibition of OPG, consistent with an in-
direct effect of thyroid hormones on osteoclast function
(254, 258, 266).Other studies, however, suggest effects of
T3 on osteoclastogenesis are independent of RANKL sig-
naling (273, 274). A further complication is that while TR
expression is well documented in osteoblastic cells, some
of the effects of T3 on bone organ cultures are extremely
rapid and involve mobilization of intracellular calcium
stores to suggest that nongenomic TR-independent ac-
tions of T3 may be relevant (275).
Overall, it is unclear whether T3 acts directly in the
osteoclast lineage, or whether its stimulatory effects on
osteoclastogenesis and bone resorption are secondary re-
sponses to direct actions of T3 in osteoblasts, osteocytes,
stromal cells or other bone marrow cell lineages.
V. Genetically modified mice (Table 1)
A. Targeting TSHR signaling
Skeletal development and growth
TSHR knockout (Tshr-/-) mice have congenital hypo-
thyroidismwith undetectable thyroid hormones and 500-
fold elevation of TSH. Tshr-/- mice are growth retarded
and usually die by 4 weeks of age (276). Nevertheless,
animals supplemented with thyroid extract fromweaning
regain normal weight by 7 weeks. Heterozygous Tshr/-
mice are euthyroid with normal linear growth. Untreated
Tshr-/- mice had a 30% reduction in BMD with evidence
of increased bone formation and resorption when ana-
lyzed during growth at 6weeks of age.Tshr-/-mice treated
with thyroid extract displayed a 20% reduction in BMD
and reduced calvarial thickness, although histomorphom-
etry responses were not reported (32). Heterozygotes had
a 6% reduction in total BMD, affecting only some skeletal
elements, no change in calvarial thickness and no differ-
ence in parameters of bone resorption or formation. These
studies were interpreted to indicate that TSH suppresses
bone remodeling, and TSH was proposed as an inhibitor
of bone formation and resorption (32). Normally, T4 and
T3 levels rise rapidly to a physiological peak at 2 weeks of
age in mice, and growth velocity is maximal at this time
(277, 278). Since Tshr-/-mice are only supplemented with
thyroid extract from weaning at around 3 weeks of age
(32, 276), they remain grossly hypothyroid at this critical
stage of skeletal development. Thus, the phenotype re-
ported in Tshr-/- mice also reflects the effects of severe
hypothyroidism followed by incomplete “catch-up”
growth and accelerated bone maturation in response to
delayed thyroid hormone replacement (138, 279–281).
Furthermore, treatment with supraphysiological doses of
T4 for 21 days resulted in increased bone resorption and
agreater lossofbone inTshr-/-mice compared towild-type
controls, suggestingTshr deficiency exacerbates bone loss
in thyrotoxicosis (140).
To investigate the relative importance of T3 and TSH
in bone development, two contrasting mouse models of
congenital hypothyroidism were compared, in which the
reciprocal relationship between thyroid hormones and
TSHwas either intact or disrupted (138).Pax8-/-mice lack
a transcription factor required for thyroid follicular cell
development (282)andhyt/hytmiceharbora loss-of-func-
tionmutation inTshr (283).Pax8-/-mice have a 2000-fold
elevation of TSH (277, 284) and a normal TSHR,whereas
hyt/hyt mice have a 2000-fold elevation of TSH but a
nonfunctional TSHR.Thus, if TSHRhas the predominant
role these mice should display opposing skeletal pheno-
types. However, Pax8-/- and hyt/hyt mice each displayed
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Table 1. Skeletal phenotype of genetically modified mice
Mouse model Genotype Systemic thyroid status Developing skeleton Adult skeleton
Congenital Hypothyroid
Pax8/ Maximal Tshr signaling Apo TR and TR No Thyroid Impaired linear growth,
delayed endochondral ossification,
reduced cortical bone,
reduced bone mineralization
Majority die by weaning; coar
T4 undetectable
T3 undetectable
TSH 1900x
TSHR mutants
Tshr/ No Tshr Thyroid hypoplasia Severe growth retardation;
impaired linear growth;
reduced mineral density;
increased bone resorption;
increased bone formation or decreased bone formation
Die by weaning unless treated
Apo TR and TR T4 undetectable Low bone mass, high bone tu
T3 undetectable Enhanced bone loss in supple
TSH 500x
TshrP556L/P556L Absent Tshr signaling Thyroid hypoplasia Impaired linear growth,
delayed endochondral ossification,
reduced cortical bone,
reduced bone mineralization
NR
(hyt/hyt) Apo TR and TR T4 0.06x
T3 0.06x
TSH 2300x
Gpb5/ No Thyrostimulin Juveniles Normal linear growth;
endochondral and intramembranous
ossification. Increased bone
volume and mineralization due
to increased osteoblastic bone
formation
Skeletal phenotype resolved
by early adulthood
(Alternative high affinity Tshr ligand) T4 0.7x, (males only)
T3 normal
TSH 3  (males only)
Adults
T4,T3 and TSH normal
Compound mutants
Tshr/Tnf/ No Tshr or TNF Treated with thyroid extract from weaning NR Amelioration of low bone ma
high bone turnover phenotyp
T4,T3 and TSH not reported
TR mutants
TR mutants
TR/ No TR1 or TR2 TR1and TR2 preserved Hypothyroid Severe growth delay;
delayed endochondral ossification;
impaired chondrocyte differentiation;
reduced mineralization
Die by weaning unlessT3 trea
T4 0.1x
T3 0.4x
TSH 2x
(GH normal)
TR1/ No TR1 or TR1 TR2 and TR2 preserved Mild hypothyroidism No growth retardation NR
T4 0.7  (males only)
T3 normal,
TSH 0.8x
TR2/ No TR2 or TR2 Mild hypothyroidism No growth retardation Reduced bone mineral density
TR1 and TR1 over-expression T4 0.8x normal endochondral ossification
T3 0.7x
TSH normal
(GH normal IGF1 low)
TR1GFP/GFP No TR2 Euthyroid Normal post natal growth NR
2  increase in TR1GFP T4, T3 and TSH normal
TR0/0 No TR Euthyroid Transient growth delay,
delayed endochondral ossification,
impaired chondrocyte differentiation,
reduced mineral deposition
Osteosclerosis, increased trab
bone volume, reduced osteoc
bone resorption
Normal TR T4 normal
T3 normal
TSH normal
(GH normal)
TR1PV/ Heterozygous dominant-negative TR receptor Euthyroid Severe persistent growth retardation;
delayed intramembranous and endochondral ossification; impaired chondrocyte differentiation; reduced mineralization
Grossly dysmorphic bones; im
cortical bone volume; reduced
T4 normal (Resistant to T4 treatment)
T3 1.2x
TSH 1.5–2x
(GH normal)
TR1R384C/ Heterozygous dominant-negative TR receptor Euthyroid adults Transient growth delay; delayed intramembranous and endochondral ossification; impaired chondrocyte differentiation Impaired bone modelling; Ost
(10  lower affinity for T3) Mild hypothyroidism (P10–35) (Ameliorated T3 treatment)
T4 0.8x
T3 0.7x
TSH 0.7x
(GH reduced in juveniles)
TR1R398H/ Heterozygous dominant-negative TR receptor Euthyroid juveniles NR NR
T4 and T3 normal
TSH 3.4x
TR1L400R/ Global expression Euthyroid Severe persistent growth retardation; delayed endochondral ossification NR
(TRAMI/xSycp1-Cre) dominant-negative T4 and T3 normal
receptor TR1L400R TSH normal
(GH low)
TR1L400R//C1 Osteoblast expression dominant-negative Euthyroid No skeletal abnormalities reported following limited analysis No skeletal abnormalities repo
(TRAMI/x Col1a1-Cre) receptor TR1L400R T4 and T3 and TSH normal
TR1L400R//C2 Chondrocyte and osteoblast expression dominant-negative Euthyroid Persistent growth retardation Short stature
(TRAMI/x Col2a1-Cre) receptor TR1L400R T4 and T3 and TSH normal Delay in endochondral ossification
Skull abnormalities
Reduced cortical and trabecular bone
Decreased mineralization
TR mutants
(Continued )
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Table 1. Continued
Mouse model Genotype Systemic thyroid status Developing skeleton Adult skeleton
TR/ No TR RTH and goitre Persistent short stature,
advanced endochondral and
intramembranous ossification,
increased mineral deposition
Osteoporosis, reduced
Normal TR T4 3–4x
T3 3–4x
TSH 2.6–8x
TR2/ No TR2 Mild RTH No growth abnormality NR
TR1 preserved T4 1–3x
T3 1.3–1.5x
TSH 1.2–2.5x
TRPV/PV Homozygous dominant-negative TR receptor Severe RTH and goitre Accelerated prenatal growth;
persistent postnatal growth
retardation; advanced intramembranous
and endochondral ossification;
increased mineralization
NR
T4 15x
T3 9x
TSH 400x
TR337T/337T Homozygous dominant-negative TR receptor Severe RTH and goitre No growth phenotype NR
T4 15x
T3 10x
TSH 50x
TR transgenics
Tshb[GRAPHIC]TRG345R Pituitary expression of dominant-negative TRG345R RTH Normal growth NR
T4 1.2x
TSH normal
Cga[GRAPHIC]TR337T Pituitary expression of dominant-negative TR337T T4 normal NR NR
TSH 3x
(Reduced bioavailability?)
Actb[GRAPHIC]TRPV ubiquitous expression of dominant-negative TRPV RTH Impaired weight gain NR
T4 1.5x
TSH normal
Cga[GRAPHIC]TRPV Pituitary expression of dominant-negative TRPV Euthyroid Impaired weight gain NR
T4, T3 and TSH normal
Compound mutants
TR/TR/ No TR1, TR2 or TR RTH and small goitre Growth delay similar to
TR/;
delayed endochondral ossification;
impaired chondrocyte
differentiation;
Die at or near weaning
TR1 and TR2 preserved T4 10x reduced mineralization
T3 10x
TSH 100x
TR1/TR/ No TR1, TR1 or TR RTH and large goitre Persistent growth retardation;
delayed endochondral ossification;
reduced mineralization
Reduced trabecular and
TR2 and TR2 preserved T4 60x mineral density
T3 60x GH treatment corrects g
TSH 160x
(GH/IGF1 low)
TR2/TR/ No TR2, TR2 or TR Mild hypothyroidism Transient growth delay NR
TR1 and TR1 over-expression T4 0.7x
T3 0.8x
TSH normal
TR0/0TR/ No TR or TR RTH and goitre More severe phenotype than TR0/0; NR
T4 14x growth delay;
delayed endochondral ossification;
impaired chondrocyte differentiation;
reduced mineralization
T3 13x
TSH 200x;
(GH/IGF1 low)
Pax8/TR1/ No TR1 or TR1 No Thyroid Growth retardation similar to
Pax8/
Die by weaning
TR2/TR2 preserved T4 undetectable
Apo TR T3 undetectable
Maximal Tshr signaling TSH NR
Pax8/TR0/0 No TR No Thyroid Growth retardation less than Pax8/and similar to TR0/0/; NR
Apo TR T4 undetectable delayed endochondral ossification; mice survive to adulthood
Maximal Tshr signaling T3 undetectable
TSH 400x
Pax8/TR/ No TR No Thyroid Growth retardation similar to Pax8/; severely delayed endochondral ossification Die by weaning
Apo TR T4 undetectable
Maximal Tshr signaling T3 undetectable
TSH 400x
Deiodinase mutants
C3H/HeJ 80% reduction in D1 activity T4 1.6x Not reported NR
T3 normal
rT3 3x
Dio1/ No Dio1 T4 1.4x Normal growth NR
T3 normal
TSH normal
rT3 4x
Dio2/ No Dio2 T4 1–1.3x Normal intramembranous and endochondral ossification Reduced bone formatio
T3 normal Increased mineralization
TSH 3–15x Brittle bones
rT3 normal
Dio3/ No Dio3 Perinatal thyrotoxicosis Reduced body length NR
Adult central hypothyroidism
Compound mutants
Dio1/ Dio2/ No Dio1 or Dio2 T4 1.7x Normal growth NR
T3 normal
(Continued )
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impaired linear growth, delayed endochondral ossifica-
tion, reduced cortical bone mass, defective trabecular
bone remodeling and reduced bone mineralization (138).
Indeed, bothPax8-/- andhyt/hytmice have impaired chon-
drocyte, osteoblast and osteoclast activities that are typ-
ical of thyroid hormone deficiency (161, 187, 189, 200,
230, 231, 246) and characteristic of juvenile hypothyroid-
ism (278–281, 285). Nevertheless, the actions of thyroid
hormone and TSH are not mutually exclusive, and the
skeletal consequences of grossly abnormal thyroid hor-
mone levels in Pax8-/- and hyt/hyt mice may mask effects
of TSH on the skeleton.
To investigate further the role of the TSHR in bone,
Gpb5-/-mice lacking the high affinity ligand thyrostimulin
were characterized. Juvenile Gpb5-/- mice had increased
bone volume and mineralization due to increased osteo-
blastic bone formation, whereas no effects on linear
growth or osteoclast function were identified. Resolution
of these abnormalities by adulthood was consistent with
transient postnatal expression of thyrostimulin in bone
(139). Despite this, treatment of osteoblasts with thyro-
stimulin in vitro had no effect on cell proliferation, dif-
ferentiation and signaling, suggesting that thyrostimulin
acts via unknown cellular and molecular mechanisms to
inhibit bone formation indirectly during skeletal
development.
Adult bone maintenance
Two animal studies have investigated the therapeutic
potential of TSH to inhibit bone turnover. Ovariecto-
mized rats were treated with TSH at doses insufficient to
alter circulating T3, T4 or TSH levels (145). Intermittent
TSH treatment resulted in reduced bone resorptionmark-
ers, but increased formationmarkers, togetherwith a dose
related increase in BMD. Bone volume, trabecular archi-
tecture and strength parameters were either preserved or
improved although no dose relationshipwas evident. This
osteoblastic response toTSH(145) contrastswith findings
inTshr-/-mice,whichalsodisplayed increasedosteoblastic
bone formation despite the absence of TSHR signaling
(32). In further studies, intermittent treatment of ovariec-
tomized rats or mice with similar concentrations of TSH
was investigated by bone densitometry and micro-CT. In
these studies TSH prevented bone loss and increased bone
mass following ovariectomy (286). Furthermore, treat-
ment of thyroidectomized and parathyroidectomized rats
with intermittent TSH injections also suppressed bone re-
sorption and stimulated bone formation resulting in in-
creased bone volume and strength (287).
B. Targeting thyroid hormone transport and metabolism
Thyroid hormone transporters
Mct8-/y knockout mice have elevated T3 but decreased
T4 levels and recapitulate the systemic thyroid abnormal-
ities observed in Allan-Herndon-Dudley syndrome.
Mct8-/y mice, however, do not display the neurological
abnormalities and exhibit onlyminor growth delay before
postnatal day P35, suggesting that other transporters such
as OATP1c1 may compensate for lack of MCT8 in mice
(288, 289). Mct10 mutant mice harbor an ENU loss-of-
function mutation and exhibit normal weight gain during
Table 1. Continued
Mouse model Genotype Systemic thyroid status Developing skeleton Adult skeleton
TSH 15x
rT3 6.5x
Transporter mutants
Mct8/ No Mct8 T4 0.7–0.3x NR NR
T3 1–1.4x
TSH 1–3x
rT3 0.2x
Mct10Y88*/Y88* No Mct10 P21: T4 normal; T3 0.8x NR NR
Adult: T4 and T3 normal
Oatp1c1/ No Oatp1c1 T4,T3 and TSH normal NR NR
Compound mutants NR NR
Mct8/ Mct10Y88*/Y88* No Mct8 or Mct10 P21: T4 0.6x; T3 1.6x NR NR
Adult: T4 normal; T3 3x
Mct8/ Oatp1c1/ No Mct10 or Oatp1c1 T4 0.3x Growth retarded after P16 NR
T3 2x
TSH 5x
Mct8/ Dio1/ No Mct8 or Dio1 T4 1.4x Mild growth retardation NR
T3 normal
TSH 1.4x
rT3 normal
Mct8/ Dio2/ No Mct8 or Dio2 T4 0.4x Mild growth retardation NR
T3 1.7x
TSH 50x
rT3 0.2x
Mct8/ Dio1/ Dio2/

No Mct8, Dio1or Dio2 T4 2.3x Growth retarded NR
T3 1.4x
TSH 100x
rT3 2x
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growth (290, 291). Furthermore, mice lacking both
MCT8 and MCT10 also showed no evidence of growth
retardation (291), suggesting both transporters are dis-
pensable in the skeleton. Similarly, Oatp1c1-/- knockout
mice exhibited normal weight gain during growth (292)
and had no evidence of growth retardation (293). How-
ever, doublemutants lacking bothMct8 andOatp1c1 had
growth retardation from P16 (292), confirming redun-
dancy among thyroid hormone transporters in the regu-
lation of skeletal growth. Finally, mice lackingMct8 and
Dio1 or Dio2 display mild growth retardation, while tri-
ple mutants lacking Mct8, Dio1 and Dio2 exhibit more
severe growth delay (288), indicating cooperation be-
tween thyroid hormone transport andmetabolism in vivo
during linear growth.
Deiodinases
A minor and transient impairment of weight gain was
reported in male Dio2-/- mice, whereas weight gain and
growth were normal in Dio1-/- and DIO1-deficient C3H/
HeJ mice, and in C3H/HeJ/Dio2-/- mutants with DIO1
and DIO2 deficiency (294–296).
The role of DIO2 in bone was investigated in Dio2-/-
mice (60),which havemild pituitary resistance toT4 char-
acterizedbya3-fold increase inTSH, a27%increase inT4
and normal T3 levels (297, 298). Bone formation and lin-
ear growth were normal inDio2-/-mice, indicating DIO2
does not have a major role during postnatal skeletal de-
velopment. This is unexpected given studies in the chick
embryonic growth plate indicating that DIO2 regulates
the pace of chondrocyte proliferation and differentiation
during early development (159). Although skeletal devel-
opment is normal, adult Dio2-/- mice have reduced bone
formation resulting in a generalized increase in bone min-
eralization and brittle bones. Target gene analysis dem-
onstrated the phenotype results from reduced T3 produc-
tion in osteoblasts (60).
Dio3-/- mice have severe growth retardation and in-
creased perinatal mortality. At weaning they have a 35%
reduction in body weight, which persists into adulthood
(299). Interpretation of the phenotype, however, is com-
plicated by the systemic effects of disruptedHPTaxismat-
uration and altered thyroid status (300).
In summary, DIO1 has no role in the skeleton; DIO2 is
essential for osteoblast function and the maintenance of
adult bone structure and strength, while the role of DIO3
in bone remains to be determined.
C. Targeting TR (Figure 7)
Analysis of TR-null, Pax8-null andTR-‘knock-in’mice
has provided further insight into the complexity of T3
actions and the relative roles of TR isoforms. Importantly,
TR1-/- and TR2-/- mice have selective deletion of TR1
or 2, TR-/- mice represent an incomplete deletion be-
cause the TR1 and TR2 isoforms are still expressed,
whereas TR0/0mice represent a complete knockout lack-
ing all Thra transcripts (73, 185, 253, 301–303).
TR1-/- mice retain normal TR2 mRNA expression
(304) and have 30% lower T4 but normal T3 levels and
20% reduced TSH, indicating mild central hypothyroid-
ism. TR1-/- mice had normal weight gain and linear
growth (304). TR1-/-TR-/- double-null mice have 60-
fold increases in T4 and T3with 160-fold higher TSH and
decreased GH and IGF-1. Juveniles had growth retarda-
tion, delayed endochondral ossification and decreased
bone mineralization, and adults had reduced trabecular
and cortical BMD (305–307).
Gene targeting to prevent TR2 expression resulted in
3–5 fold and 6–10 fold overexpression of TR1mRNA in
TR2/- and TR2-/- mice, respectively (253). TR2-/-
mice had 25% lower levels of T4, 20% lower T3, but
inappropriately normal TSH, indicatingmild thyroid dys-
function. Juvenile TR2-/-mice had normal linear growth,
but adults had reduced trabecular BMD and cortical bone
mass (253). Fusion of green fluorescent protein (GFP) to
exon 9 of Thra in TR1-GFP mice unexpectedly resulted
in loss of TR2 expression in homozygoteswith only a 2.5
fold increase in TR1mRNA (308). Homozygous TR1-
GFP mice were euthyroid with no abnormalities of post-
natal development or growth, suggesting the phenotype in
TR2-/- micemay result from abnormal overexpression of
TR1. TR2-/-TR-/- double mutants have mild hypothy-
roidism with 30% reduction in T4, 20% decrease in T3
and normal TSH, resulting in transiently delayed weight
gain (309).
TR-/- mice are markedly hypothyroid, have severely
delayed bone development and die aroundweaning unless
treatedwith T3 (73, 310, 311). The skeletal abnormalities
include delayed endochondral ossification, disorganized
growth plate architecture, impaired chondrocyte differ-
entiation and reduced bone mineralization. TR-/-TR-/-
double-nullmice have 10-fold increases in T4 andT3with
100-fold elevation of TSH and similarly display delayed
endochondral ossification and growth retardation (310,
311).
TR0/0 mice are euthyroid and have less severe skeletal
abnormalities than TR-/- mutants. Juveniles display
growth retardation, delayed endochondral ossification
and reduced bone mineral deposition. Although delayed
ossification and reduced mineral deposition were ob-
served in juvenile TR0/0 mice, adults had markedly in-
creased bone mass resulting from a bone-remodeling de-
fect (312). Deletion of both TRs in TR0/0TR-/- double-
null mice resulted in a more severe phenotype of delayed
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bone maturation that may be due to reduced GH/IGF-I
levels or reflect partialTR compensation inTR0/0 single
mutants (313).
The role of unliganded TRs in bone was studied in
Pax8-/-mice. The severely delayed endochondral ossifica-
tion inPax8-/-mice compared toTR0/0TR-/- doublemu-
tants indicates that the presence of unliganded receptors is
more detrimental to skeletal development than TR defi-
ciency. Importantly, amelioration of the Pax8-/- skeletal
phenotype in Pax8-/-TR0/0 knockout mice, but not
Pax8-/-TR-/- mutants (314), suggested that unliganded
TR is largely responsible for the severity of the Pax8-/-
skeletal phenotype. Nevertheless, this interpretation was
not supported by analysis of Pax8-/-TR1-/- mice in which
growth retardation inPax8-/-micewas not ameliorated by
additional deletion of TR1 (315).
The essential role for TR in bone has been confirmed
by studies of mice with dominant negative mutations of
Thra1. A patient with severe resistance to thyroid hor-
mone (RTH) was found to have a frameshift mutation in
the THRB gene, termed “PV”. The mutation results in
expression of a mutant TR that cannot bind T3 and acts
Figure 7.
Skeletal phenotype of TR and TR mutant mice
(A) Proximal tibias stained with alcian blue (cartilage) and van Gieson (bone, red) showing delayed formation of the secondary ossification center
in TR deficient mice (TR0/0) and grossly delayed formation in mice with dominant negative TR mutations (TR1R384C/ and TR1PV/). Mice
with mutation or deletion of TR have advanced ossification with premature growth plate narrowing.
(B) Skull vaults stained with alizarin red (bone) and alcian blue (cartilage) showing skull sutures and fontanelles. Arrows indicate delayed
intramembranous ossification in mice with dominant negative TR mutations (TR1R384C/ and TR1PV/) and advanced ossification in mice with
mutation or deletion of TR.
(C) Trabecular bone microarchitecture in adult TR mutant mice. Backscattered electron scanning electron microscopy (EM) images show increased
trabecular bone in TR0/0 mice and severe osteosclerosis in TR1R384C/ and TR1PV/ mice. By contrast, TR mutant mice have reduced trabecular
bone volume and osteoporosis.
(D) Trabecular bone micromineralization in adult TR mutant mice. Pseudocolored quantitative backscattered electron scanning EM images
showing mineralization densities in which high mineralization density is gray and low is red. Mice with deletion or mutation of TR have retention
of highly mineralized calcified cartilage (arrows) demonstrating a persistent remodeling defect. By contrast, mice with deletion or mutation of TR
have reduced bone mineralization (arrow) secondary to increased bone turnover.
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as a potent dominant-negative antagonist of wild-type TR
function (316). The homologous mutation was intro-
duced into themouseThra gene to generate TR1PVmice.
The TR1PV/PV homozygous mutation is lethal whereas
TR1PV/ heterozygotes display mild thyroid failure with
small increases in TSH and T3, but no change in T4.
TR1PV/ mice have a severe skeletal phenotype with
growth retardation, delayed intramembranous and endo-
chondral ossification, impaired chondrocyte differentia-
tion and reduced mineral deposition during growth (278,
317, 318). Adult mice had grossly abnormal skeletal mor-
phology with increased bone mass and retention of calci-
fied cartilage indicating defective bone remodeling (319).
Thus, TR1PV/ mice have markedly impaired bone de-
velopment and maintenance despite systemic euthyroid-
ism, indicating that wild-type TR signaling in bone is
impaired by the dominant-negative PV mutation in
heterozygous mice. Furthermore, the presence of a dom-
inant-negative TR leads to amore severe phenotype than
receptor deficiency alone.
TR1R384C/ mice, with a less potent dominant-nega-
tive mutation of TR, are euthyroid. They display tran-
sient growth retardation with delayed intramembranous
and endochondral ossification. Trabecular bone mass in-
creased progressively with age and adults had osteoscle-
rosis due to a remodeling defect (312). Remarkably, brief
T3 supplementation during growth, at a dose sufficient to
overcome transcriptional repression by TR1R384C, ame-
liorated the adult phenotype (312). Thus, even transient
relief from transcriptional repression mediated by unli-
ganded TR1 during development has long-term conse-
quences for adult bone structure and mineralization.
TRAMI mice harbor a floxed Thra allele [AF2 muta-
tion inducible (AMI)] and express a dominant-negative
mutant TR1L400R only after Cre-mediated recombina-
tion. Mice with global expression of TR1L400R had a
similar skeletal phenotype to TR1PV/ andTR1R384C/
mice (320). Furthermore, restricted expression of
TR1L400R in chondrocytes resulted indelayed endochon-
dral ossification, impaired linear growth and a skull base
defect (321). Microarray studies using chondrocyte RNA
revealed changes in expression of known T3-regulated
genes, but also identified new target genes associated with
cytoskeleton regulation, the primary cilium, and cell ad-
hesion. Desjardin et al also reported that restricted ex-
pression of TR1L400R in osteoblasts unexpectedly re-
sulted in no skeletal abnormalities (321).
In summary, the presence of an unliganded or mutant
TR is more detrimental to the skeleton than the absence
of the receptor. Overall, these studies (i) demonstrate the
importance of thyroid hormone signaling for normal skel-
etal development and adult bone maintenance, and (ii)
identify a critical role for TR in bone.
D. Targeting TR (Figure 7)
TwoTR-/- strains have been generated and both show
similar skeletal phenotypes (9, 285, 311–313).Mice lack-
ingTR recapitulateRTHwith increasedT4,T3andTSH
concentrations (9, 285). Juvenile TR-/- mice have accel-
erated endochondral and intramembranous ossification,
advanced bone age, increasedmineral deposition and per-
sistent short stature due to premature growth plate clo-
sure. Increased T3 target gene expression demonstrated
enhanced T3 action in skeletal cells resulting from the
effects of elevated thyroid hormones mediated by TR in
bone. Accordingly, the phenotype is typical of the skeletal
consequences of thyrotoxicosis (13, 322). In keeping with
the consequencesof thyrotoxicosis, adultTR-/-micehave
progressive osteoporosiswith reduced trabecular and cor-
tical bone, reduced mineralization and increased oste-
oclast numbers and activity (285, 312).
TRPV/PV mice with the potent dominant-negative PV
mutation have a severe RTH phenotype with a 15-fold
increase in T4, 9-fold increase in T3 and 400-fold increase
in TSH (164, 278, 317, 323). Consequently, TRPV/PV
mice have more severe abnormalities than TR-/- mice
with accelerated intrauterine growth, advanced endo-
chondral and intramembranous ossification, craniosyn-
ostosis and increasedmineral deposition again resulting in
short stature.
Overall, skeletal abnormalities in TRmutantmice are
also consistent with a predominant physiological role for
TR in bone.
Cellular and molecular mechanisms
The opposing skeletal phenotypes in mutant mice pro-
vide compelling evidence of distinct roles for TR and
TR in the skeleton and HPT axis. The contrasting phe-
notypes of TR andTRmutantmice can be explained by
the predominant expression of TR in bone (163, 164)
and TR in hypothalamus and pituitary (8, 9). Thus, in
TR mutants, delayed ossification with impaired bone
remodeling in juveniles and increased bone mass in adults
is a consequence of disrupted T3 action in skeletal T3
target cells, whereas accelerated skeletal development and
adult osteoporosis in TR mutants result from supra-
physiological stimulation of skeletal TR due to disrup-
tion of the HPT axis (318).
This paradigm is supported by analysis of T3 target
gene expression in skeletal cells, which demonstrated re-
duced skeletal T3 action in TR mutant animals (255,
278, 285, 312), and increased T3 action in TR mutant
mice (164, 224, 285, 312). The studies further demon-
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strate that T3 exerts anabolic actions during skeletal de-
velopment but catabolic actions in adult bone. The data
also indicate that effects of disrupted or increased T3 ac-
tion in bone predominate over skeletal responses to TSH.
For example, TR0/0, TR1PV/ and TR1R384C/ mice
have grossly increased trabecular bone mass even when
TSH concentrations are normal, while TR-/- and
TRPV/PV mice are osteoporotic despite markedly in-
creased levels of TSH. Consistent with this conclusion,
TR1-/--/- double knockoutmice, generated in a different
genetic background, also display reduced bone mineral-
ization despite grossly elevated TSH (305).
Although TR is the major TR isoform expressed in
bone, it is apparent TR0/0TR-/- mice have amore severe
skeletal phenotype than TR0/0 mice, while TR0/0 mice
also remain sensitive to T4 treatment, suggesting a com-
pensatory role for TR in skeletal cells. This analysis is
supported by studies of thyroidmanipulated adult TR0/0
and TR-/- mice, in which a discrete role for TR in me-
diating remodeling responses to T3 treatment was pro-
posed (167).
Downstream signaling responses in skeletal cells
GH receptor (GHR) and IGF1 receptor (IGF1R)
mRNA was reduced in growth plate chondrocytes in
TR0/0 and TR1PV/mice and phosphorylation of their
secondary messengers signal transducer and activator of
transcription 5 (STAT5) and protein kinase B (AKT) was
also impaired (278, 312). By contrast, GHR and IFG1R
expression and downstream signaling were increased in
TR-/- and TRPV/PV mice (278, 285). Furthermore, stud-
ies in osteoblasts from knockout mice revealed that T3/
TR1 bound to a response element in intron 1 of the Igf1
gene to stimulate transcription (259). These studies dem-
onstrate GH/IGF1 signaling is a downstream mediator of
T3 action in the skeleton in vivo.
Activation of FGFR1 stimulates osteoblast prolifera-
tion and differentiation (324) and FGFR3 regulates
growth plate chondrocyte maturation and linear growth
(325). Fgfr3 and Fgfr1 expression was reduced in growth
plates of TR0/0, TR1R384C/ and TR1PV/ mice and
Fgfr1 expression was reduced in osteoblasts from TR0/0
and Pax8-/- mice (138, 224, 255, 278, 285, 312). By con-
trast, Fgfr3 and Fgfr1 expression was increased in growth
plates of TR-/- and TRPV/PV mice and Fgfr1 expression
was increased in osteoblasts from TRPV/PV mice (164,
224, 285, 312). Thus, FGF/FGFR signaling is a down-
stream mediator of T3 action in chondrocytes and osteo-
blasts in vivo.
T3 is essential for cartilage matrix synthesis and hepa-
ran sulfate proteoglycans (HSPGs) are key matrix com-
ponents essential for FGF and IHH signaling. Studies in
thyroid manipulated rats and TR0/0TR-/- and Pax8-/-
mice demonstrated reduced HSPG expression in thyro-
toxic animals, increased expression in TR0/0TR-/- mice
and more markedly increased expression in hypothyroid
rats and congenitally hypothyroid Pax8-/- mice (219).
Thus, T3 coordinately regulates FGF/FGFR and IHH/
PTHrP signaling within the growth plate via regulation of
HSPG synthesis.
In neonatal TRPV/PV mice, Runx2 expression was in-
creased in perichondrial cells surrounding the developing
growth plate, and in 2-week-old mice Rankl expression
was decreased in osteoblasts (252). Although the findings
are consistent with increased canonical Wnt signaling
pathway during postnatal growth, expression of Wnt4
was decreased. Unliganded TR physically interacts with
and stabilizes -catenin to increaseWnt signaling but this
interaction is disruptedbyT3binding.However, although
TRPV similarly interacts with -catenin its interaction is
not disrupted by T3 (326), and this leads to persistent
activation of Wnt signaling in TRPV/PV mice despite re-
duced expressionofWnt4 (252).Tsourdi et al investigated
Wnt signaling in hypothyroid and thyrotoxic adult mice
(327). In hyperthyroid animals bone turnover was in-
creased and, consistent with this, the serum concentration
of theWnt inhibitorDKK1was decreased. In hypothyroid
mice bone turnover was reduced and the DKK1 concen-
tration increased. Surprisingly, however, concentrations
of another Wnt inhibitor, sclerostin, were increased in
both hyperthyroid and hypothyroid mice (327). These
preliminary studies suggest increased Wnt signaling may
also lie downstream of T3 action in bone.
VI. Skeletal consequences of mutations in thyroid
signaling genes in humans (Table 2)
A. TSHB
Loss of function mutations
Several individuals have been describedwithmutations
of TSHB leading to biologically inactive TSH and con-
genital nongoitrous hypothyroidism (OMIM #275100),
but skeletal consequences have only been documented in
two cases. Two brothers aged 10 and 7 years were de-
scribed with isolated TSH deficiency and normal BMD
following thyroid hormone replacement frombirth (328).
These cases demonstrate that absence of TSH throughout
normal skeletal development and growth does not affect
bone mineral accumulation by 10 years of age.
B. TSHR
Loss-of-function mutations
Loss-of-function mutations in TSHR have been de-
scribed atmore than 30different amino acid positions and
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Table 2. Skeletal phenotype in individuals with TSHB, TSHR, SECISBP2, THRA and THRB
mutations
Mutation Genotype Systemic thyroid status Skeletal Phenotype References
TSHB loss-of-function (Non-goitrous congenital hypothyroidism type 4 OMIM: 275 100)
TSHBQ49X/Q49X Premature stop Low T4, T3 and TSH T4 replacement from birth (328)
TSH deficiency BMD normal in two children at 7y and 10y
TSHR loss-of-function (Non-goitrous congenital hypothyroidism type 1 OMIM: 275 200)
TSHRP52A/I167N (i) Impaired function Normal T4 Normal growth and bone age (14y) (334)
(ii) Severely impaired function Elevated TSH 20x (Without T4 treatment)
TSHRR109Q/W546X (i) Impaired function Normal T4 Normal growth and bone maturation (3y) (333)
(ii) frameshift/premature stop Elevated TSH  50 (Without T4 treatment)
TSHRA553T/A553T Reduced cell surface expression Hypoplastic thyroid Normal birth length and head circumference (331)
Low T4 Normal growth (3y)
Elevated TSH  250 (T4 treatment)
TSHRC390W/ fs419X (i) Impaired function Hypoplastic thyroid Normal linear growth and bone age (5y) (332)
(ii) frameshift/premature stop Low T4 (T4 treatment)
Elevated TSH 40x
TSHRIVS6  3 GC/fs656X (i) Skipping of exon 6 Severe hypoplasia Delayed bone age/enlarged fontanelles at birth (336)
(ii) frameshift/premature stop Very low T4 Normal growth (2y)
Elevated TSH 200x (T4 replacement)
TSHRIVS5–1GA/IVS5–1GA Skipping of exon 6 Severe hypoplasia Enlarge fontanelles at birth (335)
Very low T4 and T3 Normal growth (12y)
Elevated TSH 250x (T4 replacement)
TSHR gain-of-function (Non-autoimmune hyperthyroidism OMIM: 609 152)
TSHRM453T/ Constitutive activation of cAMP Goiter Advanced bone age (539)
High T4 and T3 Normalised after treatment (12y)
Suppressed TSH
TSHRM453T/ Constitutive activation of cAMP Goiter Advanced bone age (newborn) (339)
High T4 and T3
Suppressed TSH
TSHRS505N/ Constitutive activation of cAMP High T4 and T3 Bone age advanced by 4 yr at 6 moths old (341)
Suppressed TSH Craniosynostosis
Treatment improved growth and bone age (4y)
TSHRT632I/ Constitutive activation of cAMP High T4 and T3 Craniosynostosis (344)
Suppressed TSH
TSHRF629L/ Constitutive activation Goiter Advanced bone age (338)
High T4 and T3 Craniosynostosis
Suppressed TSH Development normal after treatment (10y)
TSHRR528H/S281N (i) Polymorphism High T4 and T3 Birth length 90th centile (343)
(ii) Constitutive activation of cAMP Suppressed TSH Craniosynostosis requiring surgery
TSHRV597L/ Constitutive activation of cAMP High T4 and T3 Advanced bone age (9m) (340)
Suppressed TSH
TSHRM453T/ Constitutive activation of cAMP Goiter Bone age advanced by 5y (342)
High T4 and T3 Craniosynostosis and mid-face hypoplasia
Suppressed TSH Shortened 5th metacarpals and phalanges
TSHRT32I/ Constitutive activation High T4 and T3 Bone age advanced by 4 yr (345)
Suppressed TSH Craniosynostosis requiring surgery
Treatment stabilized bone age
(Height: 90th centile at 6months but 18th centile at 4y)
SECISBP2 loss-of-function (Abnormal thyroid hormone metabolism OMIM: 609 698)
SECISBP2R540Q/R540Q Hypomorphic allele with abnormal SECIS binding High T4 and rT3, Delayed growth and bone age (346)
low T3, Normal final height
Slightly elevated TSH;
SECISBP2K438X/IVS8DS29G-A (i) LoF truncation High T4 and rT3, Transient growth retardation (346)
(ii) Splicing defect low T3,
Slightly elevated TSH
SECISBP2R128X/R128X Truncated protein lacking N-terminal High T4 and rT3 Growth retardation and delayed bone age. (348)
low T3 Responsive to T3 treatment
normal TSH.
SECISBP2R120X/R770X (i) LoF truncation High T4 and rT3 Intrauterine growth retardation (347)
(ii) Impaired SECIS binding low T3 Craniofacial dysmorphism
Slightly elevated TSH Bilateral clinodactyly
Delayed growth and bone age
SECISBP2fs255X/ fs (i) frameshift/premature stop High T4 and rT3 Genu valgus (349)
(ii) splicing defect normal T3 External rotation of the hip
normal TSH Normal final height
SECISBP2C691R/fs (i) Increased proteasomal degradation High T4 and rT3 Delayed growth (349)
(ii) splicing defect low T3 T3 treatment improved growth
normal TSH
SECISBP2M515fs563X/Q79X (i) frameshift/premature stop High T4 Delayed growth and bone age (350)
(ii) premature stop slightly low T3 GH improved height but not bone age
Slightly elevated TSH GHT3 normalised height and bone age
RTH: THRB dominant-negative mutations (Nongoitrous congenital hypothyroidism type 6 OMIM: 614 450)
TR?/ Unknown Goitre Delayed bone maturation (351)
High T4, T3 Stippled epiphyses
Non suppressed TSH
TR?/ Unknown Goiter Normal height and body proportions (360)
High T4, T3 Normal head circumference
Non suppressed TSH Normal bone age and epiphyses (8y)
TR?/ Unknown High T4, T3 and TSH Short stature and delayed bone age. (540)
TR?/ Unknown Goiter Short stature (377)
High T4, T3 Bone age 3y at 2.9 yr old
Non suppressed TSH Craniosynostosis (9y)
Shortened 4th metacarpals and metatarsals
(Continued )
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Table 2. Continued
Mutation Genotype Systemic thyroid status Skeletal Phenotype References
TRG345R/ No T3 binding Goiter Normalizing T4 slowed growth (352)
High T4, T3
Non suppressed TSH
TRT337/T337 Dominant negative TR High T4, T3 Growth retardation (368,370)
Homozygous single amino acid deletion Markedly elevated TSH Delayed bone age
No T3 binding
TR/ Deletion of TR coding region High T4, T3 Stippled epiphyses and growth delay (541)
Non suppressed TSH
TRR438H/ Dominant negative TR Goiter Delayed bone age. (542)
Missense mutation High T4 and TSH
TRC434X/ Dominant negative TR High T4, T3 Advanced bone age (376)
C-terminal premature stop Non suppressed TSH
No T3 binding
TRR338L/ Dominant negative TR High T4, T3 Reduced bone mineral density (375)
Missense mutation Non suppressed TSH
TRM310L/ Dominant negative TR Goiter Intrauterine growth retardation (366)
Missense mutation High T4, T3 Delayed bone age
Reduced T3 affinity Non suppressed TSH Persistent short stature (17y)
TRF438fs422X/ Potent dominant negative TR Small goiter Growth retardation and delayed bone age (367)
Frameshift Very high T4, T3 Short stature
C-terminal premature stop High TSH Frontal bossing
No T3 binding
TRK443fs458X/ Potent dominant negative TR High T4, T3 and TSH Short stature (7y) (316)
Frameshift
C-terminal premature stop
No T3 binding
TRR429W/ Normal T3-binding affinity Goitre Increased osteocalcin and decreased BMD (19y) (378)
and transactivation High T4, T3
Non suppressed TSH
TRG344A/ Dominant negative TR High T4 Mild intrauterine growth retardation (364,543)
Missense mutation Non suppressed TSH Persistent short stature
No T3 binding Delayed bone age
TRG347A/ Missense mutation Goiter Persistent short stature (21y) (379)
High T4, T3 Increased bone turnover markers
Non suppressed TSH
TRA317T/; TRR438H/;
TRP453T/;
TRP453fs463X/;
TRN331H/
Missense mutations High T4, T3 Reduced whole body and lumbar spine BMD (374)
Frameshift Non suppressed or high
TSH
in adults but not in children
C-terminal premature stop
RTH: THRA dominant-negative mutations (Nongoitrous congenital hypothyroidism type 6 OMIM: 614 450)
TR1E403X/ Dominant negative TR1 Low fT4, normal fT3 Disproportionate short stature (6y) (382)
C-terminal premature stop Low fT4/fT3 ratio Epiphyseal dysgenesis and grossly delayed bone age
Low rT3 Macrocephaly and patent skull sutures
Normal TSH Delayed tooth eruption, defective bone mineralization
TR1F397fs406X/ Dominant negative TR1 Low fT4 and high fT3 Delayed bone age and persistent short stature (3y) (384,385)
Frameshift Low fT4/fT3 ratio Macrocephaly/flattened nasal bridge/patent skull
sutures
C-terminal premature stop Low rT3 Delayed tooth eruption and congenital hip dislocation
Normal TSH Brief increased growth following T4 treatment
Persistent short stature and otosclerosis (47y)
TR1A382Pfs389X/ Dominant negative TR1 Normal fT4 and fT3 Disproportionate persistent short stature (45y) (383)
Frameshift Low fT4/fT3 ratio Macrocephaly and cortical bone thickening
C-terminal premature stop Low rT3 T4 treatment (10–15y) increased growth rate
Borderline elevated TSH
TR1C392X/ C-terminal premature stop Low fT4 Delayed growth short stature with shortened limbs (388)
High fT3 Macrocephaly/flattened nasal bridge/hypertelorism
Micrognathia/elongated thorax/lumbar kyphosis (18y)
Low fT4/fT3 ratio T4 treatment did not improve syndrome
Normal TSH
TR1E403X/ Dominant negative TR1 Low normal fT4 Delayed growth short stature with shortened limbs (388)
C-terminal premature stop High normal fT3 Macrocephaly/flattened nasal bridge/hypertelorism
Low fT4/fT3 ratio Elongated thorax/lumbar kyphosis (14y)
Normal TSH T4 treatment did not improve syndrome
TR1E403K/ Missense mutation Low normal fT4 Short stature with shortened limbs (388)
High normal fT3 Macrocephaly/flattened nasal bridge/hypertelorism
Low fT4/fT3 ratio Elongated thorax (12y)
Normal TSH T4 treatment did not improve syndrome
TR1P398R/ Missense mutation Low normal fT4 Delayed growth with shortened limbs (388)
High normal fT3 Flattened nasal bridge/hypertelorism
Low fT4/fT3 ratio Elongated thorax (8y)
Low normal TSH T4 treatment did not improve syndrome
TRA263V/ Weak dominant negative Low normal fT4 Growth retardation, (389)
Missense mutation Transactivation activity
restored by supra-physiological T3
High normal fT3 Macrocephaly/broad face/flattened nasal bridge
No effect on TR2 action Low fT4/fT3 ratio Thickened calvarium
Low rT3 T4 treatment improved growth rate
Normal TSH Macrocephaly and increased BMD in adult
TRN359Y/ Dominant-negative TR1 Missense mutation
with decreased T3 binding and transactivation
activity
Normal fT4 Growth retardation with shortened limbs (390)
(Continued )
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result in varying degrees of TSH resistance and congenital
nongoitrous hypothyroidism (OMIM #275200) (329,
330). However, skeletal consequences have only been re-
ported in a few children. Individuals with mild and com-
pensated hypothyroidism have normal growth and bone
age (331–334), whereas subjects with severe thyroid hy-
poplasia and very low T4 and T3 levels have delayed in-
tramembranous ossification and bone age at birth but dis-
play normal growth and postnatal skeletal development
following T4 replacement (335, 336). These cases dem-
onstrate that impaired TSHR signaling does not impair
linear growth and bone maturation when thyroid hor-
mones are adequately replaced.
Gain-of-function mutations
Nonautoimmune autosomal dominant hyperthyroid-
ism (OMIM #609152) is rare and patients are frequently
treated at an early age with thyroid surgery and radioio-
dine ablation followed by physiological T4 replacement
(337). Skeletalmanifestations at presentation include clas-
sical features of juvenile hyperthyroidism, with advanced
bone age (338–342) craniosynostosis (338, 342–345),
shortening of fifth metacarpal bones and middle phalan-
ges of the fifth fingers (342) all described. The skeletal
consequences in treated adults have not been reported, but
in several younger patients amelioration of the phenotype
was reported following treatment and normalization of
circulating thyroid hormone levels (338, 341, 344, 345).
These cases indicate that early normalization of thyroid
status improves skeletal abnormalities in patients with
nonautoimmune autosomal dominant hyperthyroidism
despite continued constitutive activation of the TSHR.
C. SBP2
Loss-of-function mutations
The deiodinases are selenoproteins that require incor-
poration of the rare amino acid selenocysteine (Sec) for
enzyme activity. Individuals with loss-of-function muta-
tions of SBP2, which encodes the Sec incorporation se-
quence binding protein (SBP2) essential for incorporation
of Sec, have abnormal thyroid hormone metabolism re-
sulting in low circulating total and fT3 levels despite ele-
vated total and fT4 and reverse T3 levels (OMIM
#609698). Affected patients have evidence of skeletal thy-
roid hormone deficiency during prepubertal growth with
transient growth retardation, short stature and delayed
bone age (346–349) that cannot be compensated by treat-
ment with GH (350).
D. THRB
Dominant-negative mutations
Resistance to thyroid hormone (RTH), an autosomal
dominant condition caused by heterozygous dominant
negative mutations of the THRB gene encoding TR
(OMIM #188570, RTH), was described in 1967 (351)
with the first mutations identified in 1989 (352, 353). The
incidenceofRTH is 1 in40 000andover3000caseshave
been documented with 80% harboringTHRBmutations,
of which 27% are de novo (354). The mutant TR dis-
rupts negative feedback of TSH secretion resulting in the
characteristic elevation of T4 and T3 concentrations and
inappropriately normal or increased TSH. The syndrome
results in a complexmixed phenotype of hyperthyroidism
and hypothyroidism depending on the specific mutation
and target tissue. Thus, an individual patient can have
symptoms and signs of both thyroid hormone deficiency
and excess. Tissue responses to T3 are dependent upon:
the severity of the TRmutation; genetic background; the
relative concentrations of TR, wild-type TR and dom-
inant negative mutant TR proteins in individual cells;
and whether the patient has received prior treatment with
antithyroid drugs or surgery. Consequently, interpreta-
tion of the skeletal phenotype in RTH is complex and a
broad range of abnormalities has been described.
The skeletal consequences ofRTHhavebeen reported
in a limited number of patients with a spectrum of muta-
tions. Abnormalities include major or minor somatic de-
fects, such as scaphocephaly, craniosynostosis, bird-like
facies, vertebral anomalies, pigeon breast, winged scapu-
lae, prominent pectoralis, and short fourth metacarpals
(355). The findings are inconsistent and factors other than
mutations of TR may be responsible (356). In kindreds
with the same THRBmutation, individuals may have dif-
ferent phenotypes especially with respect to growth ve-
locity or the degree of abnormality in thyroid status. Thus,
Table 2. Continued
Mutation Genotype Systemic thyroid status Skeletal Phenotype References
Weak reduction in TR2 action High normal fT3 Macrocephaly/hypertelorism/micrognathia/broad nose,
Low fT4/fT3 ratio Elongated thorax with clavicular and12th rib agenesis
with Scoliosis, ovoid vertebrae and congenital hip
dislocation
Low normal rT3 Humeroradial synostosis and syndactyly
Low TSH (initially normal)
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variable skeletal abnormalities have been reported in 3
kindreds (357), in 14 affected individuals within a four-
generation kindred (358), and in four unrelated families
with affected individuals aged 14 months to 29 years
(359), while a normal skeletal phenotype was reported in
an affected 8-year-old (360).
Some subjects have been reported with skeletal abnor-
malities that are similar to the consequences of hypothy-
roidism. Delayed growth fifth percentile has been esti-
mated in 20% of subjects with growth retardation alone
in 4% (361), while delayed bone age of  2 SD was re-
ported to occur in 29%–47% (362). AnNIH study of 104
patients from 42 kindreds and 114 unaffected relatives
found short stature in 18%, lowweight-for-height in 32%
of children, and variable tissue resistance from kindred to
kindred. RTH patients were shorter than unaffected
family members and had no catch-up growth later in life.
However, delayed bone age was documented in only a
minority (363). In a study of 36 family members with
RTH in four generations, delayed bone maturation with
short staturewas observed in affected adults and children.
Ofnote, inaffected individualsborn toanaffectedmother,
growth retardation was less marked. Seven of eight chil-
dren with RTH, but only one of six controls, had bone
age 2SDbelowmean (364).Delayed bonematurationwas
also found in a series of 8 children (365). In individual
cases stippled epiphyses were reported in a 6 year old
(351), intra-uterine and postnatal growth retardation
with delayed bone age in a 26-month old girl (366), and
delayed bone age  3SD below mean for chronological
age in a 22 month-old (367). Four patients with homozy-
gousTHRBmutations have been identified andmarkedly
delayed linear growth and skeletal maturation were re-
ported (368–370).
Other individuals with RTH, however, have been re-
ported with skeletal abnormalities that are similar to the
consequences of hyperthyroidism. Short metacarpals,
metatarsals and advanced bone age have all been de-
scribed (371), as well as craniofacial abnormalities, cra-
niosynostosis, advanced bone age, short stature, osteopo-
rosis and fracture, together with increased bone turnover
and changes in calcium, phosphorous andmagnesiumme-
tabolism (364, 372, 373). In 14 patients, including eight
adults and six children, the affected children had short
stature below the third centile, no significant delay in bone
age, increased calcium, decreased phosphate and elevated
FGF23. Adults had low lumbar spine and whole body
BMD (374). Five adults from two unrelated kindredswith
same THRB mutation were followed for 3–11 years and
found to have reduced BMD (375). In individual cases, a
15 year old girl with short stature and advanced bone age
equivalent to age 17 years (376) was reported; craniosyn-
ostosis with frontal bossing andminor skeletal abnormal-
ities including short metacarpals were seen in a 9-year-old
(377); a 19-year-old man with increased osteocalcin and
mildly reduced BMD was reported (378); and a 21-year-
old female with short stature, normal alkaline phospha-
tase but elevated urinary deoxypyridinolinewas described
(379).
Overall, these findings should be considered in the con-
text of data frommousemodels ofRTH. Inmutantmice,
the skeletal phenotype is consistentwith increased thyroid
hormone action in bone manifest by accelerated skeletal
development in juveniles and increased bone turnover
with osteoporosis in adults (318). Importantly, the clear
and consistent findings in mutant mice result from studies
of single mutations in genetically homogeneous back-
grounds that are not confounded by therapeutic interven-
tion. Reports in human RTH result from patients with a
broad range of mutations of varying severity studied in
diverse genetic backgrounds. Phenotype diversity is also
likely to be due to additional confounding factors includ-
ing; variable phenotype analyses and nomenclature
among studies, retrospective and cross-sectional study de-
sign, differing surgical and pharmacological interven-
tions, and analysis of individuals at differing ages. Well-
controlled long-term prospective analysis of large families
with specific mutations will be the only way to determine
the skeletal consequences of individual mutations in hu-
man RTH.
E. THRA
Dominant-negative mutations
Individuals with mutations of THRA encoding TR
were recently identified (OMIM #614450, RTH) and
this has resulted in reclassification of the inheritable syn-
dromes of impaired sensitivity to thyroid hormone (380).
By analogy to the phenotype variability seen in RTH, it
was considered likely that individuals with a spectrum of
THRA mutations would be identified (381). Heterozy-
gousmutations ofTHRAwere first reported in three fam-
ilies in 2012 and 2013 (382–385). Affected individuals all
had grossly delayed skeletal development but variablemo-
tor and cognitive abnormalities. All had normal serum
TSHwith low/normal T4 and high/normal T3 concentra-
tions, and a characteristically reduced fT4:fT3 ratio (369,
386, 387).
Mutations affecting TR1
A 6-year-old girl had skeletal dysplasia, growth retar-
dation with grossly delayed bone age and tooth eruption,
patent skull sutures with wormian bones, macrocephaly,
flattened nasal bridge, disproportionate short stature (de-
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creased subischial leg length with a normal sitting height),
epiphyseal dysgenesis and defective bone mineralization
(382).A3-year-oldgirl displayeda similarphenotypewith
short stature, macrocephaly, delayed closure of the skull
sutures, delayed tooth eruption, delayed bone age with
absent hip secondary ossification centers and congenital
hip dislocation. Treatment with T4 resulted in a brief ini-
tial catch-up of growth, whereas GH treatment had no
effect. Her subsequent height, however, remained 2 SD
below normal. Her 47-year-old father was short (-3.77
SD) but with normal BMD and he had hearing loss due to
otosclerosis (384, 385). A 45-year-old female was subse-
quently describedwith disproportionate short stature and
macrocephaly (head circumference9 SD), together with
skull vault and long-bone cortical thickening. Between the
ages of 10 and 15 years, T4 treatment increased her rate of
growth, although final adult height was 2.34 SD below
predicted (383).Most recently, a series of four individuals
with truncating and missense mutations affecting TR1
was described and included data from 18 years follow-up
(388). A consistent skeletal phenotype included dispro-
portionate growth retardationwith relatively short limbs,
hands and feet and a long thorax, and a mild skeletal
dysplasia comprising flat nasal bridge with round, puffy
and coarse flattened facial features, upturned nose, hy-
pertelorism and macrocephaly. Radiological features of
hypothyroidism included: ovoid immature vertebral bod-
ies, ossification defects of lower thoracic and upper lum-
bar bodies and hypoplasia of the acetabular and supra-
acetabular portions of the ilia, and coxa vara. Hand
X-rays showed changes in the tubular bones, which were
abnormally short, wide and physically disabled. A phe-
notype-genotype correlationwasnotedwithmissensemu-
tations associated with a milder phenotype than the more
severe phenotype seen in individuals with THRA trunca-
tion mutations. T4 treatment had no effect in any patient
(388).
Mutations affecting both TR1 and 2
A 60-year-old woman presented in childhood with
growth failure, macrocephaly, broad face, flattened nasal
bridge and a thickened calvarium (389). Her growth im-
proved after T4 treatment during childhood following a
radiological opinion suggesting the skeletal features were
similar to hypothyroidism. Her 30 and 26 year-old sons
presented similarly and were also treated during child-
hood, resulting in a good growth response. Nevertheless,
they each had a persistently abnormal facial appearance
andmacrocephaly, togetherwith increasedBMDbetween
0.8 and1.9 SD. In vitro studies demonstrated the mu-
tant TR1 was a weak dominant negative antagonist but
its transcriptional activity could be restored by supra-
physiological concentrations of T3, whereas the function
of the mutant TR2 protein did not differ from wild-type
(389). Recently, a 27-year-old female with a grossly ab-
normal skeletal phenotype and low FT4:FT3 ratio was
described in associationwith aN359Ymutation affecting
both TR1 and 2 (390). Her phenotype included intra-
uterine growth retardation (IUGR) and failure to thrive,
macrocephaly, hypertelorism, micrognathia, short and
broad nose, clavicular and 12th rib agenesis, elongated
thorax, ovoid vertebrae, scoliosis, congenital hip disloca-
tion, short limbs, humeroradial synostosis, and syndactyly
(390). This severe and atypical phenotype extends the ab-
normalities described in patients with THRA mutations,
and raises questions regarding whether TR2 has a func-
tional role in skeletal development or whether the RTH
phenotype is more variable and extensive than previously
reported.
Together, these reports define a new genetic disorder,
RTH, characterized by profound and consistent devel-
opmental abnormalities of the skeleton that recapitulate
findings in mice with dominant negative Thra mutations
(278, 312, 319–321, 391). Initially identified THRAmu-
tations resulted in severe phenotypes due to expression of
truncated TR1 proteins with no T3-binding capability
but potent dominant-negative activity (382–385). Recog-
nition of individuals with milder mutations and pheno-
types has been predicted to be more difficult because dis-
ruption of THRA does not affect the HPT axis
significantly (319).
VII. Thyroid status and skeletal development
A. Consequences of hypothyroidism
Hypothyroidism is the most common congenital endo-
crine disorder with an incidence of 1 in 1800. Congenital
and juvenile acquired hypothyroidism result in delayed
skeletal development and bone agewith short stature. Ab-
normal endochondral ossification and epiphyseal dysgen-
esis are evidenced by “stippled epiphyses” on X-rays. In
severe or undiagnosed cases (Figure 8) there is complete
postnatal growth arrest and cessation of bone maturation
with a complex skeletal dysplasia that includes broad flat
nasal bridge, hypertelorism, broad face, patent fonta-
nelles, scoliosis, vertebral immaturity and absence of os-
sification centers, and congenital hip dislocation (392).
Thyroid hormone replacement induces rapid ‘catch up’
growth and accelerated skeletal maturation, demonstrat-
ing the exquisite sensitivity of the developing skeleton to
thyroid hormones. Nevertheless, predicted adult height
may not be attained and, in such cases, the final height
deficit is related to the duration and severity of hypothy-
roidism prior to diagnosis and treatment (281), although
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the underlying mechanisms remain unknown. Overall,
most children with congenital hypothyroidism that are
treated early with thyroxine replacement ultimately reach
their predictedadult height andachievenormalBMDafter
85 years follow-up (393, 394).
B. Consequences of thyrotoxicosis
During skeletal development and growth, T3 regulates
the pace of chondrocyte differentiation in the epiphyseal
growth plates (120, 159, 161, 162, 224). Graves’ disease
is the commonest cause of thyrotoxicosis in children but
remains rare. In contrast to hypothyroidism during child-
hood, juvenile thyrotoxicosis is characterized by acceler-
ated skeletal development and rapid growth, although ad-
vanced bone age results in early cessation of growth and
persistent short stature due to premature fusion of the
growth plates. In severe cases in young children, early clo-
sure of the cranial sutures can result in craniosynostosis
(13, 322, 345), while maternal hyperthyroidism per se
may also be a risk factor for craniosynostosis (395). These
observations demonstrate further the marked sensitivity
of developing skeleton to the actions of thyroid hormone.
VIII. Thyroid status and bone maintenance
Numerous studies have investigated the consequences
of altered thyroid function on BMD and fracture risk in
adults (396–399). Interpretation is difficult as studies are
frequently confounded by inclusion of subjects with a va-
riety of thyroid diseases and comparison of cohorts that
include combinations of pre- andpostmenopausalwomen
or men (400–405). Many studies lack statistical power
because of small numbers, cross-sectional design or insuf-
ficient follow-up (401, 406–411). Some studies measure
TSHbut not thyroid hormones, whereas others determine
thyroid hormones but notTSH (402,
408). Other problems include inad-
equate control for confounding fac-
tors including: age; prior or family
history of fracture; body mass index
(BMI); physical activity; use of estro-
gens, glucocorticoids, bisphospho-
nates or vitamin D; prior history of
thyroid disease or use of thyroxine;
and smoking or alcohol intake.
Different methods have also been
used for skeletal assessment, includ-
ing analysis of bone geometry in
some studies (411, 412). Regulation
of bone turnover has been investi-
gated by histomorphometry in early
studies (413–416), measurement of
proinflammatory cytokines (417)
and a variety of biochemicalmarkers
of bone formation [serum alkaline
phosphatase, osteocalcin, car-
boxyterminal propeptide of type 1
collagen (P1NP)] and resorption
[urinary pyridinoline and deoxypyr-
idinoline collagen cross-links, hy-
droxyproline, carboxyterminal
cross-linked telopeptide of type 1
collagen (CTX), cathepsin K], which
are all elevated in hyperthyroidism
and generally correlate with disease
severity (401, 408, 418–422). Over-
all, hyperthyroidism shortens the
bone remodeling cycle in favor of in-
creased resorption (Figure 5). This
results in a high bone turnover state
Figure 8.
X-rays of a 36 year-old female with severe untreated congenital hypothyroidism
(X-rays kindly provided by Dr. Jonathan LoPresti, Keck School of Medicine, University of Southern
California)
(A) Lateral and AP skull images showing persistently patent sutures and fontanelles and delayed
tooth eruption.
(B) Lower limb X-ray showing severe epiphyseal dysgenesis with grossly delayed formation of
secondary ossification centers (arrows).
(C) Hand X-ray demonstrating a 35-year delay in bone maturation (bone age 14 months).
(D) Bone age advanced by 8 years following T4 replacement for a period of only 18 months,
demonstrating rapid acceleration of endochondral ossification and “catch up growth”.
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with increased bone resorption and formation rates. The
frequency of initiation of bone remodeling is also in-
creased. The duration of bone formation and mineraliza-
tion is reduced to a greater extent than the duration of
bone resorption. This leads to reduced bone mineraliza-
tion, a net 10% loss of bone per remodeling cycle and
osteoporosis (415). BMD has also been determined by
several methods including dual x-ray absorptiometry
(DXA), single-photon absorptiometry (SPA), dual-pho-
tonabsorptiometry (DPA),quantitative computed tomog-
raphy (CT) (QCT) (398), ultrasound (400), and high res-
olution peripheral QCT (HR-pQCT) (423). Although
many retrospective and cross-sectional studies of the ef-
fects of thyroid dysfunction on bone turnover and mass
have been reported, only a small number of studies have
been prospective, while even fewer have investigated frac-
ture susceptibility. Interpretationof the literature is, there-
fore, difficult and complex.
Discriminating thyroid hormone and TSH effects on the
skeleton
Studies investigatingosteoporosis, fracture and thyroid
hormone excess have been conflicting regarding the rela-
tive roles of thyroid hormone and TSH (424). Impor-
tantly, this issue cannotbe resolved in individuals inwhom
the HPT-axis is intact and the reciprocal relationship be-
tween thyroid hormones and TSH is maintained (13).
Nevertheless, simultaneously increased thyroid hormone
and TSH signaling occurs in three clinical situations: non-
autoimmune autosomal dominant hyperthyroidism and
RTH, as described above, together with Graves’ disease,
in which TSHR-stimulating antibodies persistently acti-
vate the TSHR and increase T4 and T3 production. Con-
ventionally, secondary osteoporosis in Graves’ disease is
considered to be a consequence of elevated circulating thy-
roid hormone levels and increased T3 actions in bone. By
contrast, TSH has been proposed as a negative regulator
of bone remodeling (32) and thus suppressedTSH levels in
thyrotoxicosis were suggested to be the primary cause of
bone loss. Nevertheless, since Graves’ disease is charac-
terized by persistent autoantibody-mediated TSHR stim-
ulation, such patients should be protected. Despite this,
Graves’ disease remains an established and important
cause of secondary osteoporosis and fracture.
The effects of TSH on bone turnover have also been
investigated in clinical studies. In patients receiving TSH-
suppressive doses of T4 in the management of differenti-
ated thyroid cancer, administration of recombinant hu-
man (rh) TSH (rhTSH) increases TSH levels to  100
mU/L but does not affect circulating T4 and T3 concen-
trations as patients have previously undergone total thy-
roidectomy. In this context, treatment of premenopausal
women with rhTSH had no effect on serum markers of
bone turnover (425–427). Inpostmenopausalwomen two
studies reported a reduction in bone resorption markers
accompanied by an increase in bone formation markers
following rhTSH administration (426, 427), while two
studies reported no effect (425, 428).
A. Consequences of variation of thyroid status within
the reference range
Effect on bone turnover markers
No studies have been reported in premenopausal
women. In 3261 postmenopausal women from the Study
of Health in Pomerania, higher TSH was associated with
increased bone turnover and stiffness but no association
was reported with levels of sclerostin. In 2654 men from
the same study, however, TSH was not related to bone
turnover, stiffness or sclerostin. Importantly, T3 and T4
levels were not determined in this study (429). In a study
of 60 postmenopausal women, Zofkova et al reported a
correlation between high TSH and low concentrations of
the bone resorption marker urinary deoxypyridinoline,
but no relationshipwith thebone formationmarker serum
procollagen type I C propeptide (PICP) (430), although
individuals with treated hypothyroidism, subclinical hy-
perthyroidism and secondary hyperparathyroidism were
included.
Effect on BMD
One study in 2957 euthyroid healthy Taiwanese men
and women of varying ages reported a weak inverse cor-
relation between fT4 and BMD but did not identify any
relationship between TSH and BMD (431).
A 6-year prospective study of 1278 healthy euthyroid
postmenopausal women from 5 European cities (OPUS
study) found that thyroid status at the upper end of the
normal rangewas associatedwith lower BMD (432). This
finding has been supported by a number of cross-sectional
studies. Thyroid function in the upper normal reference
range was associated with reduced BMD in 1426 healthy
euthyroid peri-menopausal women (433). A study of 756
euthyroidKoreanwomenaged65andolder showedBMD
was positively correlated with TSH (434). In 581 post-
menopausal American women, TSH at the lower end of
the reference range was associated with a 5-fold increased
risk of osteoporosis compared to TSH at the upper end of
the normal range (435). Kim et al (436) showed that low
normal TSH levels were associated with lower BMD in
959Korean postmenopausalwomen. In 648healthy post-
menopausal women, higher fT4 levels within the normal
range were associated with a relationship with deteriora-
tion in trabecular bone microarchitecture (437).
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In 1151 euthyroid men and women over the age of 55
years femoral neck BMD correlated positively with TSH
and inverselywith free T4 (438). The associationwith free
T4 was much stronger than the association with TSH. A
population study of 993 postmenopausal women and 968
men from Tromso showed that subjects with TSH below
the 2.5th percentile had a low forearm BMD whereas
those with TSH above the 97.5th percentile had high fem-
oral neck BMD (439). A study of 677 healthy men aged
between 25–45 years found that higher fT3, total T3 and
total T4 levels were associated with lower BMD (440).
Fracture risk
Leader et al investigated 13 325 healthy subjects with
at least one TSH measurement during 2004 and demon-
strated an increased risk of hip fracture during the subse-
quent 10 years in euthyroid womenwith TSH levels in the
lower normal range, although no effect was found in men
(441). Svare et al analyzed prospective data from over
16 000 women and nearly 9000 men in the Hunt2 study
and found no relationship between baseline TSH and hip
or forearm fracture, but weak positive associations in
women between hip fracture risk and both low and high
TSH (442). In 130 postmenopausal women with normal
thyroid function, Mazzioti et al (443) found that TSH
levels at the low end of the normal range were associated
with an increased prevalence of vertebral fractures in
women previously known to have osteoporosis or os-
teopenia. Van der Deure et al (438), however, found no
relationship between fT4 or TSH and fracture in 1151
euthyroidmen andwomen over the age of 55 years. In the
OPUS study thyroid status at the upper end of the normal
range was associated with an increased risk of incident
nonvertebral fracture, which was increased by 20% and
33% in women with higher fT4 or fT3, whereas higher
TSH was protective and the fracture risk was reduced by
35% (432). However, in a 10-year prospective study of a
cohort of only 367 women, no associations between fT3,
fT4 or TSHand incident vertebral fracturewere identified
(444).
Overall, thyroid status at theupper endof the euthyroid
reference range is associated with lower BMD and an in-
creased risk of fracture in postmenopausal women, al-
though studies cannot discriminate the relative contribu-
tions of thyroid hormones and TSH.
B. Consequences of hypothyroidism
The effects of hypothyroidism on bone turnover have
been investigated by histomorphometry (413, 416).Man-
ifestations include reduced osteoblast activity, impaired
osteoid apposition and a prolonged period of secondary
bonemineralization. Consistent with a low bone turnover
state, osteoclast activity and bone resorption are also re-
duced. The effect is a net increase in mineralization with-
out a major change in bone volume, although bone mass
may increase as a result of the prolonged remodeling cycle
(413, 445). To identify changes in bone mass resulting
from hypothyroidism would require long-term follow up
of untreated patients, and data from such studies are not
available.
Effect on bone turnover markers
No studies have been reported in pre- or postmeno-
pausal women or men.
Effect on BMD
Consistent with histomorphometry data, two studies
reported normal BMD in patients newly diagnosed with
hypothyroidism (446, 447). A cross-sectional cohort
study of 49patientswithwell-substituted hypothyroidism
was compared to 49 age-and sex-matched controls inves-
tigated BMDbyDXA, bone geometry by pQCT and bone
strength by finite element analysis. The study showed no
difference between controls andpatients receiving thyrox-
ine (423). A retrospective study of 400 Puerto Rican post-
menopausal women also showed no relationship between
hypothyroidism and BMD (448). Nevertheless, Paul et al
(449) reported a 10% reduction in BMD in the femur but
no effect on lumbar spine BMD following T4 replacement
in 31 hypothyroid premenopausal women treated for at
least 5 years, while Kung et al (450) reported reduced
BMD in 26 hypothyroid premenopausal women receiving
T4 for between 1–24 years. These studies are difficult to
interpret because of the confounding effects of patient
compliance to T4 replacement and the likely variability in
the adequacy or sustainment of restored euthyroidism
during follow-up.
Fracture risk
Although the effects on fracture risk of T4 replacement
for hypothyroidism have not been investigated directly,
retrospective data failed to identify an association (451–
453). Nevertheless, large cross-sectional population stud-
ies have identified anassociationbetweenhypothyroidism
and fracture. Patients with a prior history of hypothyroid-
ism or increased TSH concentration had a 2–3 fold in-
creased relative risk of fracture, which persisted for up to
10 years following diagnosis (447, 454–457). One recent
study of thyroxine treatment of 74 patients with adult-
onset hypopituitarism also suggested the possibility that
overtreatment of patients with T4 may increase vertebral
fracture risk in some patients, particularly those with co-
existent untreated GH deficiency (458).
In postmenopausal women a database cohort study of
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11 155 women over 65 receiving thyroxine for hypothy-
roidism revealed an increased risk of fracture in patients
with a prior history of osteoporosis who were receiving
more than 150 g of T4, suggesting overtreatment is det-
rimental (459). Nevertheless, Gonzalez-Rodriguez et al
did not identify a relationship between hypothyroidism
and fracture in Puerto Rican postmenopausal women
(448).
Overall, these studies suggest that hypothyroidism per
se is unlikely to be related to fracture risk, whereas long-
term supraphysiological replacement with thyroid hor-
mones may result in an increased risk of fracture.
C. Consequences of subclinical hypothyroidism
Effect on bone turnover markers
A randomized controlled trial (RCT) in a heteroge-
neous group of 61 patients with subclinical hypothyroid-
ism demonstrated that treatment with T4 to restore eu-
thyroidism resulted in increased bone turnover at 24 and
48 weeks and reduced BMD after 48 weeks (460).
Effect on BMD and fracture risk
A study of subclinical hypothyroidism in 4936 USmen
and women aged 65 years and older followed up for 12
years showed no association with BMD or incident hip
fracture (461). A prospective study in men aged 65 and
older over 4.6 years follow-upalso revealednoassociation
between subclinical hypothyroidism and bone loss (462).
A prospective cohort study of 3567 community dwelling
men over 65 years revealed a 2.3 fold increased risk of hip
fracture over 13 years follow-up in men with subclinical
hypothyroidism following adjustment for covariates, in-
cluding use of thyroid hormones (463).
Meta-analysis
Importantly, an individual participantmeta-analysis of
70 298 individuals during 762 401 person-years follow
up foundno association between subclinical hypothyroid-
ism and fracture risk (464).
D. Consequences of subclinical hyperthyroidism
Effect on bone turnover markers
Management of patients with differentiated thyroid
cancer frequently involves prolonged treatmentwithT4at
doses that suppress TSH and may be detrimental to bone.
A fewstudies investigated the effectofTSHsuppressionon
bone turnover in small numbers of patients and findings
have been inconsistent (398). Some reported increased
bone formation and resorptionmarkers in patients receiv-
ing T4 (401, 465), whereas others reported no effect on
either resorption or formation markers (409, 466).
Effect on BMD
Most studies in premenopausal women reported no ef-
fect of TSH suppression therapy on BMD at any anatom-
ical site, althoughone study showedBMDmaybe reduced
(467). Early studies reporting the effect of TSH suppres-
sion on BMD in postmenopausal women were conflicting
as they frequently evaluated TSH only without measure-
mentof thyroidhormonesandwere thusunable to exclude
overt hyperthyroidism. Overall, therefore, these hetero-
geneous studies should be interpreted with caution. For
example, Franklyn et al investigated 26 UK postmeno-
pausal women treated for 8 years and found no effect of
TSH suppression on BMD (468), whereas Kung et al stud-
ied46postmenopausalAsianwomenand founddecreased
total body, lumbar spine and femoral neck BMD (469).
Direct comparison between these studies is not possible,
however, because TSH was fully suppressed in only 80%
of patients in one (468), mean calcium intake was low in
the other (469), while both were performed in small num-
bers of patients but from differing ethnic backgrounds.
Similar conflicting data have been reported at various an-
atomical sites in many less well-controlled cross-sectional
and longitudinal studies (398, 409, 410).Recent datahave
similarly been contradictory; a 12-year follow-up study of
endogenous subclinical hyperthyroidism in 1317men and
women aged 65 years and older showed no association
with BMD (461). Despite this, a 1-year prospective study
of 93 women with differentiated thyroid cancer showed
thatTSH-suppressive therapy resulted in accelerated bone
loss in postmenopausal women, but only in the early post-
operative period following thyroidectomy (403). In men,
no association between subclinical hyperthyroidism and
BMD was identified in two recent studies (461, 462),
which support overall findings from previous cross-sec-
tional studies, of which only one reported reduced BMD
in men receiving TSH-suppressive doses of T4 (470).
Fracture risk
In a retrospective population studyof 2004 individuals,
subclinical hyperthyroidism was associated with a 1.25-
fold increased risk of fracture although no association
with TSH concentration was identified and the relation-
ship between fracture and thyroid hormone levels was not
reported (471). Nevertheless, a nested case-control study
of 213 511 individuals from Ontario reported a 1.9-fold
increased fracture risk in patients treated with T4 and
demonstrated a clear dose response relationship (472). A
prospective cohort study in postmenopausal women with
case-cohort sampling identified an association between
suppressedTSHand increased fracture risk,with 3–4 fold
increases in both hip and vertebral fractures in individuals
with TSH suppressed below 0.01 mU/L (473). A 2.5 fold
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increased rate of hospital admission for fracture in sub-
jects with TSH less than 0.05 mU/L (455), and an expo-
nential rise in the association between fracture risk and
longer duration of TSH suppression (474) have also been
reported. Further analysis demonstrated an increased risk
of fracture in patients with hypothyroidism that was
strongly related to the cumulative durationof periodswith
a low TSH due to excessive thyroid hormone replacement
(475). Similarly, in the Fracture Intervention Trial, Jamal
et al analyzed a subgroup of patientswithTSH suppressed
below 0.5 mIU/L and found an increased risk of vertebral
fracture (476), although individuals with untreated thy-
rotoxicosis were not formally excluded.
Recently, Lee et al demonstrated in a 14-year prospec-
tive follow-up study that men, but not women, with en-
dogenous subclinical hyperthyroidism had a 5-fold in-
creased hazard ratio (HR) of hip fracture, while men with
all causes of subclinical hyperthyroidism had a 3-fold in-
creased HR (463). Nevertheless, a prospective study in
men aged 65 and older revealed no association between
subclinical hyperthyroidism and fracture risk during 4.6
years follow-up, although a weak increased risk of hip
fractures in subjects with lower serumTSHwas identified
(462). No association was seen between hip fracture risk
and endogenous subclinical hyperthyroidism in 4936 US
men and women aged 65 years and older followed up for
12 years (461).
In summary, large population studies have revealed in-
creased bone turnover, reduced BMD and an increased
risk of fracture particularly in postmenopausal women
with subclinical hyperthyroidism (447, 455, 456, 473).
Importantly, a prospective studyof low-risk differentiated
thyroid cancer patients treated with suppressive doses of
T4 demonstrated an increased risk of postoperative os-
teoporosis without beneficial effect on tumor recurrence,
and the authors suggested that future intervention in the
long-term treatment of low risk disease should focus to-
wards avoiding therapeutic harm (477).
Systematic reviews and meta-analyses
Levels of bone resorption and formation markers have
been reported tobe either elevatedornormal in subclinical
hyperthyroidism. Similarly, BMD has been found to be
either reduced or unaffected, and a comprehensive meta-
analysis was inconclusive (478). Heemstra et al analyzed
12 cross-sectional and 4 prospective studies of premeno-
pausal women receiving suppressive doses of T4, but
found that a formalmeta-analysis could not be performed
due to heterogeneity (397). The authors concluded that
suppressive doses of T4 are unlikely to affect BMD in
premenopausal women. This conclusion supported an
earlier review of 8 studies by Quan et al (479). A meta-
analysis of 27 studies investigating effects of TSH sup-
pression on BMD identified no effect in premenopausal
women ormen, but found that suppressive doses of T4 for
up to10years inpostmenopausalwomen led to reductions
in BMD of between 5%–7% (480). Systematic reviews of
effects in postmenopausal women receiving suppressive
doses of T4 for approximately 8.5 years suggested an in-
creased rate of annual bone loss that results in a reduction
of BMD at the lumbar spine of 7% and hip of 5%. These
reviews recommended monitoring BMD in postmeno-
pausal women with subclinical hyperthyroidism (397,
398, 479). Nevertheless, although a recent systematic re-
view and meta-analysis of 7 population-based cohorts
also suggested that subclinical hyperthyroidism may be
associatedwith an increased risk of hip and nonspine frac-
ture, a firm conclusion could not be reached due to limi-
tations of the cohorts (481).
Importantly, the largest meta-analysis of 70 298 indi-
viduals during 762 401 person-years of follow up dem-
onstrated an increased risk of hip and other fractures in
individualswith subclinical hyperthyroidism, particularly
in those with TSH suppressed below 0.1 mIU/L and those
with endogenous disease (464).
E. Consequences of hyperthyroidism
Effect on bone turnover markers and BMD
The effects of thyrotoxicosis on bone turnover are con-
sistentwith histomorphometry data.Markers of bone for-
mation and resorption are elevated and correlate with dis-
ease severity in pre- and postmenopausal women andmen
(418–421). In premenopausal women, treatment of thy-
rotoxicosis resulted in a 4% increase in BMD within one
year (482).
Fracture risk
Severe osteoporosis due to uncontrolled thyrotoxicosis
is now rare because of prompt diagnosis and treatment,
although undiagnosed hyperthyroidism is an important
contributor to secondary bone loss and osteoporosis in
patients presenting with fracture (483). The presence of
thyroid disease as a comorbidity factor has also been sug-
gested to increase 1- and 2-year mortality rates in elderly
patients with hip fracture (484). Several studies have in-
vestigated the skeleton in untreated thyrotoxicosis or have
performed population studies to determine the relation-
ship between hyperthyroidism and fracture. One cross-
sectional (456) and four population studies identified an
association between fracture and a prior history of thy-
rotoxicosis. These studies could not determine whether
reduced BMD or thyrotoxicosis were causally related to
fracture risk, although one prospective study (451) dem-
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onstrated that a prior history of thyroid disease was in-
dependently associatedwithhip fracture following adjust-
ment for BMD. Bauer et al (473, 485) demonstrated that
low TSH was associated with a 3–4 fold increased risk of
fracture even though a specific relationship between TSH
and BMDwas not identified. In agreement, Franklyn et al
identified an increased standardizedmortality ratio due to
hip fracture in a follow-up population register study of
patients treated with radioiodine for hyperthyroidism
(486). One cross-sectional study (487) identified an asso-
ciation between fracture and a prior history of thyrotox-
icosis in postmenopausal women. A large population
study reported persistence of an increased risk of fracture
5 years after initial diagnosis (456), but others failed to
demonstrate a relationship between history of thyrotox-
icosis and fracture (452, 488). Recently, however, popu-
lation studies have shown reduced BMD and an increased
risk of fracture in postmenopausal womenwith thyrotox-
icosis (447, 455, 456, 464, 473).
Systematic reviews and meta-analyses
A meta-analysis of 20 studies of patients with thyro-
toxicosis calculated that BMDwas reduced at the time of
diagnosis and there was an increased risk of hip fracture;
further investigation of the effect of antithyroid treatment
demonstrated the low BMD at diagnosis returned to nor-
mal after 5 years (489).
IX. Osteoporosis and genetic variation in thyroid
signaling
Associations with BMD
GWAS in osteoporosis cohorts have not identified as-
sociations between variation in thyroid-related genes and
BMD or fracture (490–492).
Candidate gene studies have investigated relationships
between polymorphisms in the TSHR, THRA andDIO2
genes and BMD. The TSHR D727E polymorphism was
associated with serum TSH concentration and with os-
teoporosis diagnosed by qUS in 150 male subjects com-
pared to 150 controls, whereas the D36H polymorphism
was not (493). By contrast, in 156 patients treated for
differentiated thyroid cancer the TSHR D727E polymor-
phism was associated with higher BMD at the femoral
neck independent of thyroid status, but this association
did not persist following adjustment for BMI (494). A
similar association between TSHR D727E and increased
BMD at the femoral neck was identified in 1327 subjects
from the Rotterdam study (438).
A candidate gene association study of 862men over 65
investigated genetic variation in THRA and BMD at the
femoral neck and lumbar spine (495, 496), while a much
larger study investigated the THRA locus in relation to
BMD, fracture risk and bone geometry in 27 326 individ-
uals from the Genetic Factors for Osteoporosis (GEFOS)
consortium and the Rotterdam Study 1 and 2 populations
(497). Both studies failed to identify any relationship be-
tween variation in bone parameters and genetic variation
across theTHRA locus. In a further study, a cohort of 100
healthy euthyroid postmenopausal women with the high-
est BMD was selected from the OPUS population, and
sequencing of THRA revealed no abnormalities, indicat-
ing thatTHRAmutations are not a common cause of high
BMD (498). Yerges et al, however, identified an associa-
tion between an intronic SNP in THRB and trabecular
BMD in the MrOS study (495).
Variation in deiodinases has been described as a po-
tential genetic determinant of bone pathology. Two stud-
ies investigated the relationship between deiodinase poly-
morphisms and skeletal parameters. The DIO2 T92A
polymorphism was associated with decreased femoral
neck and total hip BMDand severalmarkers of bone turn-
over in 154 athyreotic patients treated for differentiated
thyroid cancer (499), suggesting a role for DIO2 in the
regulation of bone formation. However, in 641 young
healthy men, no relationships between DIO1 or DIO2
variants and bone mass were identified (500). Sequencing
of DIO2 in healthy euthyroid postmenopausal women
with high BMD from the OPUS population also failed to
identify any abnormalities (498).
X. Osteoarthritis and genetic variation in thyroid
signaling
Genetics
A role for thyroid hormones in the pathogenesis of OA
has been proposed (501). A GWAS of siblings with gen-
eralized OA found a nonsynonymous coding variant
(rs225014; T92A) that identified DIO2 as a disease-sus-
ceptibility locus (502). An allele sharing approach rein-
forced evidence of linkage in the region of this locus (503).
Replication studies confirmed this by identifying an asso-
ciation between symptomatic OA and aDIO2 haplotype
containing the minor allele of rs225014 and major allele
of rs12885300 (504). The relationship between these
DIO2 SNPs and OA, however, was not replicated in the
Rotterdam Study population (505), and DIO2 was not
identified in recent meta-analyses (506, 507). Neverthe-
less, additional data suggested the risk allele of rs225014
may be expressed at higher levels than the protective allele
inOAcartilage fromheterozygouspatients (508), possibly
because of epigenetic modifications (509). Increased
DIO2 mRNA and protein expression has also been doc-
umented by RT-qPCR and immunohistochemistry in car-
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tilage from joints affected by end-stage OA (508, 510).
Furthermore, the rs12885300 DIO2 polymorphism has
been suggested to influence the association between hip
shape andOA susceptibility by increasing vulnerability of
articular cartilage to abnormal hip morphology (511).
Moreover, studies in transgenic rats that overexpress hu-
man DIO2 in chondrocytes indicate these animals had
increased susceptibility to OA following provocation sur-
gery (510). Finally, a meta-analysis studying genes that
regulate thyroid hormone metabolism and mediate T3 ef-
fects on chondrocytes identified DIO3 as a disease mod-
ifying locus in OA (504).
Together, thesedata suggest that localT3availability in
joint tissues may play a role in articular cartilage renewal
and repair, particularly as the associatedDIO2 andDIO3
polymorphisms do not influence systemic thyroid status
(16).Overall, increasedT3availabilitymaybedetrimental
to joint maintenance and articular cartilage homeostasis.
Mechanism
AdultDio2-/- mice have normal articular cartilage and
noother features of spontaneous joint damage, but exhibit
increased subchondral bone mineral content (512). In a
forced exercise provocation modelDio2-/-mice were pro-
tected from articular cartilage damage (513). In studies
demonstrating that functional DIO2 enzyme is restricted
to bone-forming osteoblasts, we showedDio2mRNA ex-
pression does not necessarily correlate with enzyme activ-
ity (61). An important reason for this discrepancy is that
DIO2 protein is labile, undergoing rapid degradation fol-
lowing exposure to increasing concentrations of T4 in a
local feedback loop (50, 159). We demonstrated Dio2
mRNA in growth plate cartilage but could not detect en-
zyme activity using a high sensitivity assay (61), whereas
others showed Dio2 mRNA expression in rat articular
cartilage (510), and increased levels of DIO2 mRNA
(510) and protein (508) in human articular cartilage from
joints resected for end-stage OA. In each case, however,
enzyme activity was not determined. The significance of
increasedDIO2mRNA in end-stageOAcartilage is there-
fore uncertain; it is also unknown whether increased
DIO2 expressionmight represent a secondary response to
joint destruction or whether it precedes cartilage damage
and might be a causative factor in disease progression.
Transgenic rats overexpressing DIO2 in chondrocytes
had increased susceptibility to OA following surgical
provocation (510). Nevertheless, a causal relationship be-
tween increased DIO2 expression and OA susceptibility
was not established because enzyme activity was not de-
termined (510). This is particularly important because in
a previous study, transgenic mice overexpressingDio2 in
the heart surprisingly displayed only mild thyrotoxic
changes in cardiomyocytes (514), likely because the phe-
notype was mitigated by T4-induced degradation of the
overexpressed enzyme (159). Furthermore, siRNA-medi-
ated inhibition ofDIO2 in primary human chondrocytes
resulted in decreased expression of liver X receptor 
(LXR) and increased expressionof interleukin-1 (IL1)
and IL1-induced cyclooxygenase-2 (COX2) expression
(515). Thus, in contrast to the previous studies, these find-
ings suggest that suppression of Dio2 results in a proin-
flammatory response in cartilage. The increase in DIO2
expression observed in end-stage human OA (508, 510)
may, therefore, be a consequence of disease progression
resulting from activation of proinflammatory pathways
such as the NFB pathway, which is known to stimulate
Dio2 expression (516, 517).
Although chondrocytes resist terminal differentiation
in healthy articular cartilage, a process resembling endo-
chondral ossification occurs duringOA inwhich articular
chondrocytes undergo hypertrophic differentiation with
accelerated cartilage mineralization (518, 519). AD-
AMTS5 (520, 521) and MMP13 (522) degrade cartilage
matrix and these enzymes are regulated by T3 in the
growth plate (205, 222, 223, 523, 524). In articular car-
tilage, thyroid hormones stimulate terminal chondrocyte
differentiation (525) and tissue transglutaminase activity
(526). In cocultures of chondrocytes derived from differ-
ent articular cartilage zones, interactions between chon-
drocytes from differing zones were identified that modu-
lated responses toT3andweremediated inpartbyPTHrP.
The authors proposed that communication between zones
might regulate postnatal articular cartilage organization
and mineralization (527).
Currently, the pathophysiological importance of these
studies is difficult to evaluate. Initial genetic studies sug-
gesting that reduced DIO2 activity is associated with in-
creased susceptibility to OA (502) were based on the as-
sumption that the T92A polymorphism results in reduced
enzyme activity (528). However, studies showing that
transgenic rats overexpressing DIO2 in articular cartilage
had increased susceptibility to OA (510) were not consis-
tent with this conclusion, and recent findings of allelic
imbalance and increased expression of DIO2 protein in
OA cartilage (508, 509) further suggest increased DIO2
activity may be detrimental for articular cartilage main-
tenance. On the other hand a large GWAS and recent
meta-analyses failed to identifyDIO2 as a disease suscep-
tibility locus for OA (505–507), while a recent study in
primary human chondrocytes suggests an anti-inflamma-
tory role for DIO2 in cartilage (515). Thus, it remains
unclear whether variation in DIO2 plays a role in osteo-
arthritis pathogenesis, although the independent identifi-
cation ofDIO3 as a disease susceptibility locus (504) sup-
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ports a role for control of local tissue T3 availability in the
regulation of joint homeostasis.
XI. Summary and future directions
The skeleton is exquisitely sensitive to thyroid hor-
mones, which have profound effects on bone develop-
ment, linear growth and adult bone maintenance.
Thyroid hormone deficiency in children results in ces-
sation of growth and bonematuration, whereas thyrotox-
icosis accelerates these processes. In adults, thyrotoxicosis
is an important and established cause of secondary osteo-
porosis, and an increased risk of fracture has now been
demonstrated in subclinical hyperthyroidism. Further-
more, even thyroid status at the upper end of the normal
euthyroid reference range is associated with an increased
risk of fracture in postmenopausal women.
An extensive series of studies in genetically modified
mice has shown that T3 exerts anabolic actions on the
developing skeleton, has catabolic effects in adulthood,
and these actions are mediated predominantly by TR1.
The importance of the local regulation of T3 availability
in bone has been demonstrated in studies that identified a
critical role for DIO2 in osteoblasts to optimize bonemin-
eralization and strength. The translational importance
and clinical relevance of such studies is highlighted by the
characterizationofmice harboringdeletions or dominant-
negative mutations of Thra, which accurately predicted
the abnormalities seen in patients recently identified with
RTH. Moreover, mice with dominant-negative muta-
tions ofThra also represent an important diseasemodel in
which to investigate novel therapeutic approaches in these
patients. In addition to studies in genetically modified
mice, analysis of patients with thyroid disease or inherited
disorders of T3 action is consistent with a major physio-
logical role for T3 in the regulation of skeletal develop-
ment and adult bonemaintenance.Analysis ofTshr-/-mice
and studies of TSH administration in rodents have also
suggested that TSH acts as a negative regulator of bone
turnover. Nevertheless, the physiological role of TSH in
the skeleton remains uncertain, as its proposed actions are
notwholly consistentwith findings in human diseases and
mousemodels in which the physiological inverse relation-
ship between thyroid hormones and TSH is dissociated.
Precise determination of the cellular and molecular
mechanisms of T3 and TSH actions in the skeleton in vivo
will require cell-specific conditional gene targeting ap-
proaches in individual bone cell lineages. Combined with
genome-wide gene expression analysis, these approaches
will determine key target genes and downstream signaling
pathways and have the potential to identify new thera-
peutic targets for skeletal disease.
Recent studies have also identifiedDIO2 andDIO3 as
disease susceptibility loci for osteoarthritis, a major de-
generative disease of increasing prevalence in the ageing
population. These data establish a new field of research
and further highlight the fundamental importance of un-
derstanding the mechanisms of T3 action in cartilage and
bone, and its role in tissuemaintenance, response to injury
and pathogenesis of degenerative disease.
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